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REGULATION OF AUTOIMMUNE GERMINAL CENTER REACTION BY Tfh 
CELLS AND APPLICATION OF Tfr-LIKE CELLS FOR THE TREATMENT OF 
AUTOIMMUNE B CELL RESPONSES 
 
Young Uk Kim, Ph.D. 
Advisory Professor: Yeonseok Chung, Ph.D. 
 
Excessive follicular helper T (Tfh) cell responses to self-antigens are associated with 
antibody-mediated autoimmune diseases in humans including systemic lupus erythematosus 
(SLE). Numeral and functional aberrations of T regulatory T (Treg) cells are common in 
patients with autoimmune diseases. Although different types of immunosuppressive agents 
have been used clinically to treat antibody-mediated autoimmune diseases, they generally 
have side effects due to the lack of target-specificity. To minimalize the adverse effects, there 
is a need to develop target-specific therapeutics which specifically control auto-reactive B 
cell responses and auto-reactive Tfh cell responses. Recent studies unveiled that Foxp3
+
 Treg 
cells expressing CXCR5 can migrate into the germinal center (GC) zone where they 
specifically suppress GC reactions in vivo, presumably by directly suppressing B cells and/or 
Tfh cells. These CXCR5
+
 Foxp3
+
 Treg cells are termed as follicular regulatory T (Tfr) cells. 
Due to their ability to specifically suppress Tfh cell and GC B cell responses, use of Tfr cells 
may be a promising target-specific therapy for the treatment of autoantibody-mediated 
autoimmune diseases. To evaluate the role of Tfr cells in autoantibody-mediated autoimmune 
vi 
 
diseases, we employed a BXD2 mouse model of spontaneous autoimmune lupus. Immune 
balance between Tfh and Tfr cell responses is crucial for the prevention of self-destructive 
antibody generation. However, the contribution of Tfh cells and Tfr cells to auto-reactive B 
cell responses in the BXD2 strain had not been evaluated. Therefore, we examined Tfh, Tfr 
and other relevant immune cellular responses in this autoimmune strain. We found no 
differences in both the frequency of Th17 cells and the levels of IL-17 in the circulation 
between wild-type and BXD2 mice. By contrast, the frequency of Tfh cells was significantly 
increased, and the numbers of Tfh cells were positively correlated with the levels of 
autoantibodies. In addition, we observed that IL-21-producing Tfh cells, but not IL-17-
producing Th17 cells, efficiently promoted the production of IgG from BXD2 B cells in vitro. 
These results supported the role of Tfh cells in the development of auto-reactive B cell 
responses. In addition, the frequency of Tfr cells was reduced in BXD2 mice. Therefore, 
imbalance between Tfh cells and Tfr cells in BXD2 mice likely caused the self-destructive 
antibody generation, thereby providing additional support that Tfr cell-based immunotherapy 
may ameliorate antibody-mediated autoimmunity. Unfortunately, sufficient numbers of Tfr 
cells that will be required for immunotherapy will be difficult to obtain since they are only 
found in low frequency in vivo. To address this problem, we employed retroviral transduction 
of CXCR5 onto Foxp3
+
 Treg cells, which are more abundant and less difficult to purify than 
Tfr cells. We termed these engineered CXCR5 overexpressing Foxp3
+
 Treg cells as eTfr 
cells. We demonstrated that transduction of CXCR5 in the eTfr cells did not affect the 
expression of other genes important for Treg or Tfh cell function. Furthermore, eTFr cells 
migrated in response to CXCL13 and had T cell suppressive capacity in vitro, demonstrating 
that eTfr cells maintained critical Tfr cell-like properties in vitro and were potentially a cell 
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source for Tfr cell-based immunotherapy. To test the therapeutic potential of the eTfr cells, 
we performed in vivo adoptive co-transfer experiments using TCRβ-deficient mice. 
Unfortunately, the results from these in vivo investigations were inconclusive, indicating the 
further refinement of the model system will be required to determine the viability of the eTfr 
therapeutic approach for the autoantibody-mediated autoimmune disease. In summary, we 
demonstrated that imbalance between Tfh cell and Tfr cells and IL-21, produced by Tfh 
cells, lead to auto-reactive GC B cell responses in BXD2 mice, suggesting that similar 
imbalances may have relevance in human autoantibody-mediated autoimmune diseases. 
Moreover, eTfr cells can migrate in response to CXCL13 and suppress T cell responses in 
vitro, supporting the possibility that eTfr cells may provide a novel immunotherapeutic 
approach for the treatment of antibody-mediated autoimmune disorders. 
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CHAPTER 1 
 
 
 
General Introduction 
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1. Autoimmune diseases 
Autoimmune diseases contain more than 100 different types of disorders 
characterized with various pathogenesis [1]. Many of the pathogenic mechanisms causing 
autoimmunity are not clearly defined, in general, however, failure of apoptosis of self-
reactive lymphocytes (T and B cell), defects in number and function of regulatory T (Treg) 
cells, inadequate function of inhibitory molecules, and abnormal activation of antigen 
presenting cells (APCs) are known to cause autoimmune reactions [2]. Moreover, genetic 
susceptibility, epigenetic, hormones, and environmental factors are also associated with 
development of autoimmune diseases [3]. There are two major types of autoimmune diseases; 
T cell-mediated and autoantibody-producing B cell-mediated autoimmune diseases. Among 
them, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple 
sclerosis (MS), and Sjögren’s syndrome are characterized by the existence of auto-reactive T 
cells and/or the development of auto-reactive B cell producing specific autoantibodies [4]. 
General features of each antibody-mediated autoimmune disease and its pathogenic 
mechanism are described in Table 1.  
  
３ 
 
Table 1. List of autoantibody-mediated autoimmune diseases and their clinical 
symptoms and mechanisms 
Disease Major Clinical Manifestations Disease mechanism 
Systemic lupus 
erythematosus 
Inflammation of tissues, 
glomerulonephritis, vasculitis, rash 
Autoantibodies and auto-reactive 
T cells against DNA and 
nucleoprotein antigens 
Rheumatoid  
arthritis 
Inflammation of the joints,  
joint stiffness and pain,  
loss of range of motion 
Autoantibodies and auto-reactive 
T and B cells against  
joint-associated antigens 
Multiple  
sclerosis 
Formation of sclerotic plaque in brain, 
leading to muscle weakness, ataxia, 
and other symptoms 
Autoantibodies and auto-reactive 
T cells against brain antigens 
Sjögren’s  
syndrome 
Inflammation in salivary and lacrimal 
glands, dry eyes and mouth 
Autoantibodies and auto-reactive  
T cells against apoptotic cells 
Adapted with permission from Gharagozloo M, Majewski S, and Foldvari M, Therapeutic 
applications of nanomedicine in autoimmune diseases: From immunosuppression to 
tolerance induction. Nanomedicine, 2015. 11(4): p. 1003-1018. 
 
1.1. Systemic Lupus Erythematosus 
SLE is one of the representative autoimmune disorders caused by excessive 
autoantibodies to self-antigens. Production of multiple polyclonal autoantibodies, which 
causes irreversible tissue damages, is a common clinical manifestation of SLE [5]. 
Dysregulation of adaptive immunity and overproduction of autoantibodies leads to chronic 
inflammation in multiple organs, such as skin, joints, kidney, serous membranes, central 
nervous system and blood [5]. SLE predominantly affects women, particularly during their 
４ 
 
pregnancy, and has strong genetic and environmental components [6]. Symptoms of SLE 
may vary with the individual, common symptoms of SLE include fever, fatigue, anorexia, 
myalgia, and weight loss [7]. Currently, there is no cure for SLE and therapeutics used only 
relieve the symptoms [2].  
1.2. Current clinical therapeutics in autoimmune diseases 
  Currently, several non-biological agents (Chemical based) and biologics 
(recombinant proteins and antibodies) are being used for the treatment of autoimmune 
diseases (Table 2). In the past, treatment of autoimmune diseases has primarily focused on 
the induction of systemic immunosuppression, interfering with the activation and migration 
of immune cell, or cell-targeted immune suppression [2]. For instance, non-biological 
reagents such as cyclosporine and cyclophosphamide suppress a broad range of immune 
reactions including pathologic autoimmune responses. On the other hand, biological reagents 
regulate immune responses by blocking pro-inflammatory cytokines or targeting pathogenic 
immune cell types (see table 2). There is currently no cure for SLE, and to control symptoms 
non-biological reagents such as Prednisone and Methotrexate are prescribed, which suppress 
a broad range of immune reactions [2]. However, these therapeutics suppress systemic 
immune responses broadly and thus can lead to several side effects such as renal, 
gastrointestinal, neurologic, hematologic, immunologic toxicities or increase the risk of 
developing certain types of cancer [2, 8]. Generation of auto-reactive autoantibody is 
mediated by certain types of T cells including Tfh cells [9]. However, these drugs have no 
target specificity for the inhibition of Tfh cells and auto-reactive B cells. The development of 
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alternative therapies with specificity is, therefore, urgently needed for the treatment of 
autoantibody-mediated autoimmune diseases in humans.  
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Table 2. Current clinical immunosuppressive therapies in some autoimmune diseases. 
 Therapeutic group Agent Mechanism of action Indications 
Non-
biological 
Glucocorticoid 
Prednisone, 
methylprednisolone 
Inhibit many processes 
involved in immune 
response and inflammation 
MS, RA,  
SLE 
 Calcineurin inhibitor Cyclosporin 
Block T cell activation and  
IL-2 production 
RA 
 Anti-metabolite 
Azathioprine, 
Leflunomide, 
Mycophenolate mofetil  
Methotrexate 
Interfere with the 
synthesis of culeic acids 
and cell proliferation 
RA, SLE 
 Anti-proliferative Sirolimus Inhibit T cell proliferation SLE, RA 
Biological Anti-cytokines    
 IL-1 Anakinra IL-1 receptor antagonist RA 
 IL-6 Tocilizumab Inhibit IL-6 signaling RA 
 TNFα 
Infliximab, Adalimumab, 
Golimumab, 
Cerolizumab,  
Etanecept 
Block TNFα activities RA 
 
Anti-cell surface 
ligands 
   
 CTLA4 Abatacept Block T cell co-receptors RA 
 CD20 
Rituximab, Crelizumab, 
Ofatuaumab 
Target and deplete B cells RA 
 α4 integrin Natalizumab 
Blocking cell adhesion 
and migration 
MS 
 
Immuno-modulating 
proteins 
   
 IFNβ Betaferon Suppress T cell activity MS 
 Glatiramer acetate Copaxon Suppress T cell activity MS 
 
Intravenous 
immunoglobulin 
IVIg 
Suppress or neutralize 
autoantibodies, activated 
complement components, 
and inflammatory cytokines 
MS 
Adapted with permission from Gharagozloo M, Majewski S, and Foldvari M, Therapeutic 
applications of nanomedicine in autoimmune diseases: From immunosuppression to 
tolerance induction. Nanomedicine, 2015. 11(4): p. 1003-1018.  
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1.3. Role of T helper cell subsets in autoimmune diseases 
T helper cells are key cellular regulators of the immune response. Upon antigen-
specific stimulation through the T cell receptor, naïve CD4
+
 T cells can be differentiated into 
different subsets of T helper (Th) cells depending upon different stimulatory conditions such 
as costimulatory signals as well as cytokines produced by antigen-presenting cells (Figure 1) 
[10]. In particular, the types of cytokine stimulation, termed ‘signal 3’, are known to be 
essential for activated T cells to acquire distinct transcription factors that govern each helper 
T cell lineage. Among diverse Th cell lineages, follicular helper T (Tfh) cells play a crucial 
role in controlling B cell maturation within germinal center (GC) during normal immune 
responses [9, 11]. GC is a histologically distinct structure that develops within B cell zones 
of secondary lymphoid tissues, where B cell affinity maturation, somatic hypermutation and 
selection, class switch recombination (CSR), plasma cell (PC) differentiation, and memory B 
cell differentiation occurs [9]. While Tfh cells are necessary for humoral immune responses 
to infectious pathogens and cancerous cells, excessive Tfh responses likely facilitate 
autoimmune B cell responses by promoting production of autoantibodies [12, 13]. The 
existence of autoantibodies is a hallmark of a number of autoimmune diseases. Escaping B 
cell tolerance against self-antigens results in the development of autoantibodies [13]. 
Increased Tfh responses are strongly associated with systemic autoimmunities, such as SLE, 
and spontaneous generation of GCs and expansion of Tfh cells are primary features of SLE 
[13-15]. 
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Figure 1. The differentiation of CD4
+
 T cell subsets. Effector Th cell differentiation. Upon 
encountering antigen presented by professional APCs, naive CD4
+
 T cells differentiate into 
effector subsets (Th1, Th2, Th17, Treg and Tfh) that are characterized by their cytokine 
production, expression of transcription factors and chemokine receptors, and immune 
regulatory functions. (APC, antigen-presenting cell; Bcl6, B-cell lymphoma 6; CCR, CC 
chemokine receptor; CXCR, CXC receptor; Foxp3, Forkhead box p3; IFN, interferon; ROR, 
retinoic acid-related orphan receptor; Tfh, T follicular helper; TGF, transforming growth 
factor; Th, T helper; Treg, regulatory T) 
 
Adapted with permission from Nurieva RI and Chung Y, Understanding the development 
and function of T follicular helper cells. Cell Mol Immunol, 2010. 7(3): p. 190-7  
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1.4. Role of regulatory T cells in autoimmune diseases 
The disruption of immune tolerance to self-antigens by T cells and B cells is 
consistently observed in autoimmune conditions. However, the underlying mechanisms of 
this phenomenon by which self-reactive immune cells escape from immune tolerance and 
regulatory mechanisms remain incompletely understood [16]. Understanding the cellular and 
molecular mechanisms of how auto-reactive immune cells are controlled will allow us to 
develop alternative therapeutic approaches for the treatment of autoimmune diseases.  
Deletion or mutation of Foxp3 in mice or humans causes multi-organ autoimmunity, 
inflammatory disease, and allergy [17]. The Foxp3 expressing Treg cell population is the key 
component of peripheral tolerance. Numeral and functional abnormalities of Treg cells are 
common in patients with SLE and RA [18]. In a lupus-prone animal model of autoimmune 
disease, transfer of ex vivo expanded Treg cells showed relevant improvements in renal 
disease severities and survivals [19]. An increase of Tfh cells is positively correlated with 
autoantibody titers and disease symptoms and severity in many autoantibody-mediated 
autoimmune diseases [20-22]. Recent studies have described that different types of Treg 
subsets regulate distinct T helper cell responses [23]. In 2011, three independent groups 
reported follicular regulatory T (Tfr) cells as a specialized subset of Treg cells suppressing 
germinal center reactions in vivo (Table 3) [24-26]. Moreover, the number of circulating 
CD4
+
Foxp3
+
CXCR5
+
 T cells from SLE patients is critically fewer than in healthy controls 
[27]. Therefore, a more complete understanding of the Tfh-specific regulation at a 
mechanistic level would greatly assist the development of target-specific therapeutics for the 
treatment of antibody-mediated autoimmune diseases.  
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Table 3. Diverse subsets of Foxp3
+
 regulatory T cells 
Subsets 
Transcription 
factor 
Chemokine 
receptor 
Function Ref. 
Th1 
Treg 
Foxp3 
T-bet 
CXCR3
+
 
T-bet
+
 Foxp3
+
 Treg cells express 
CXCR3 and colocalize with Th1 cells 
[28-31] 
Th2 
Treg 
Foxp3 
IRF4 
GATA3 
 
IRF4-mediated CTLA4 expression on 
Foxp3
+
 Treg cells has a disproportionate 
effect on Th2 cells 
[28, 32] 
Th17 
Treg 
Foxp3 
STAT3 
 
STAT3-mediated IL-10 expression by 
Foxp3
+
 Treg cells has a disproportionate 
effect on Th17 cells 
[28, 31, 33] 
Tfr 
Foxp3 
Bcl-6 
CXCR5
+
 
Bcl-6 induced expression of CXCR5 on 
Foxp3
+
 Treg cells enables Tfr cells to 
migrate into B cell follicles 
[24, 25, 28] 
Adapted with permission from Chang JH and Chung Y, Regulatory T cells in B cell follicles. 
Immune Netw, 2014. 14(5): p. 227-36. 
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2. Follicular helper T cells 
Depending on the types and levels of costimulation and environmental cytokines, 
naïve CD4
+
 T cells can be differentiated into different subsets of Th cells. Among them, 
follicular helper T (Tfh) cells are a specialized Th cell subset that induces the differentiation 
of B cells into PCs and memory B cells, and are essential for GC formation, affinity 
maturation as well as CSR of immunoglobulins (Ig) [11]. In the 1960s, the concept of Tfh 
cells was first suggested based on the fact that Th cells are required for the development of 
antibody responses [34, 35]. Numerous studies supported the helper role of CD4
+
 T cells for 
the development of GC, a distinct structure in secondary lymphoid organs where B cell 
maturation and high-affinity B cell selection occur [36]. However, which Th subset was 
engaged in helping B cells has remained unclear for decades. The C-X-C chemokine receptor 
type 5 (CXCR5), mainly expressed in B cells was discovered [37] and shown to be critical 
for the migration of B cells into follicles in lymphoid organs [38]. The expression of CXCR5 
was also found in a subpopulation of activated Th cells in the secondary lymphoid organs 
from immunized mice, and its expression was essential for the migration of Th cells into 
follicles [39]. CXCR5-expressing CD4
+
 T cells in human tonsils enhanced immunoglobulin 
production from B cells in vitro compared to CXCR5-negative CD4
+
 T cells obtained from 
the same tonsil [40, 41], and they were mainly localized in GCs [42]. This CXCR5 
expressing CD4
+
 T cell subset was also found in mouse lymph nodes [43]. These cells help B 
cells by secreting cytokine IL-21 [44] as well as by providing activating signal CD40 ligand 
(CD40L) [45, 46]. The transcriptional repressor B-cell lymphoma 6 protein (Bcl-6) was 
discovered to be essential for the generation of Tfh cells in vivo in animal models [47-49].  
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Tfh cells express CXCR5, ICOS, programmed cell death protein 1 (PD-1), basic leucine 
zipper transcription factor ATF-like (BATF), signal transducer and activator of transcription 
3 (STAT3), c-Maf and interferon regulatory factor 4 (IRF4), Achaete-scute complex 
homolog 2 (Ascl2), as well as the cytokines IL-21, IL-4 and IL-10 [11]. Other surface 
molecules, such as CD40L, B and T lymphocyte attenuator (BTLA), CD84, and SAP, are 
also expressed in Tfh cells.  The simplified schematic germinal center reaction is described in 
Figure 2. 
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Figure 2. The overview of germinal center reaction. Activated antigen-specific T cells in 
the T cell zone upregulate ICOS, PD-1, and CXCR5 and migrate to the B cell follicles. After 
interacting with their cognate B cells, these T cells differentiated into Tfh cells. When 
follicular B cells encounter antigen, they move to the border of the T cell zone and can 
further differentiate into extrafollicular plasmablasts, generate early memory B cells or re-
enter to the follicle and form a GC. In the GC, interactions of TCR:MHC, CD28:B7, 
CD40:CD40L, ICOS: ICOSL; SLAM:SAP, PD-1:PDL-1, and IL-21:IL-21R between Tfh 
and GC B cells are important for GC formation. Cytokines from Tfh cells, particularly IL-4 
and IL-21, influence the generation of affinity-matured memory B cells and long-lived 
plasma cells. 
Adapted with permission from Nutt SL and Tarlinton DM, Germinal center B and follicular 
helper T cells: siblings, cousins or just good friends? Nat. Immunol, 2011. 12(6): p. 472-7. 
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2.1. Tfh cell differentiation 
Tfh cell differentiation is a multi-step and multi-signal process [11], which is initiated 
by dendritic cell (DC) priming of a naïve CD4
+
 T cell [50]. Concomitant upregulation of 
CXCR5 by Bcl-6 [47-49] and Ascl2 [51], and downregulation of CCR7 and PSGL-1 
expression [52, 53] migrate Tfh precursor cells to the border of the B cell follicle and interact 
with antigen-presenting B cells at the border of the B cell follicle and the T cell zone [39, 53].  
IL-6, ICOS, IL-2 and T cell receptor (TCR) signal strength are known as key 
regulatory factors during early Tfh cell differentiation [11]. Upon TCR signal and non-TCR 
signal combination, naïve T cells can be differentiated into different effector cell types. High 
TCR affinity possessing CD4
+
 T cells preferentially differentiate into Tfh cells in a pigeon 
cytochrome C model [54], but not in a Friend virus infection [55]. IL-6 induces transient Bcl-
6 expression by newly activated CD4
+
 T cells [48]. The Bcl-6 expression is required for early 
CXCR5 expression in Tfh cells in multiple models [56-58]. Since IL-6 is also necessary for 
Th17 cell differentiation, other stimulatory signals may be involved in Tfh cell differentiation. 
ICOS is important for Tfh cell differentiation [59] and migration [60]. Several studies also 
described the importance of ICOS in Tfh cells. Roquin inhibits ICOS and deficiency of 
Roquin1 and Roquin2 results in spontaneous GC development and Tfh cells [61, 62]. 
Phosphatidylinositol-3-OH kinase (PI3K) pathway is the only known ICOS downstream 
signal pathway [63, 64] and the miR-19~72 complex is necessary for Tfh cell differentiation 
and migration by suppressing the expression of a phosphatase PHLPP2, and partially PTEN, 
which are inhibitors of ICOS signaling [65, 66]. Antigen-specific B cells in the follicle 
provide ICOSL [59], and the ICOS-ICOSL interaction induces directional migration of CD4
+
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T cells to the B cell follicle [60]. IL-2 plays a suppressive role in Tfh cell differentiation and 
can act early during T cell priming by inducing STAT5-mediated Blimp-1 [67, 68].  
Other factors are also involved in Tfh cell differentiation. Foxp1 is a critical negative 
regulator of Tfh cell differentiation [69]. By regulating IL-21 and ICOS, Foxp1 suppresses 
Tfh cell differentiation. Naïve CD4
+
 T cells from Foxp1-deficient mice preferentially 
differentiate into Tfh cells and show enhanced GC and antibody responses. A transcription 
factor Foxo1 binds to the Bcl-6 promoter region [70], and is also a target of E3 ubiquitin 
ligase Itch [71]. By ubiquitinating and degrading Foxo1, Itch regulates Bcl-6 expression. 
CD4
+
 T cells from Itch-deficient mice show reduced expression of Bcl-6 and low frequencies 
of Tfh cells [71]. This result is in conflict with a previous study, which showed a positive 
correlation between Bcl-6 gene expression and binding of Foxo1 in the Bcl-6 promoter [70]. 
2.1.1. Germinal center resident Tfh cell differentiation 
After Tfh precursor cells interact with GC B cells at the T:B border, migration into 
and retention in the follicles are necessary for GC-resident Tfh (GC Tfh) cells. Most of the 
GC-resident Tfh cells are CXCR5
hi 
PD1
hi 
Bcl6
hi 
Maf
hi 
SAP
hi 
PSGL1
lo 
CD200
+ 
BTLA
hi 
CCR7
lo
 and secrete C-X-C motif chemokine 13 (CXCL13), IL-21 and IL-4 [9, 11]. Adhesion 
molecules on GC Tfh cells have key roles in regulating their interaction with GC B cells and 
localization. The signaling lymphocyte activation molecule (SLAM) family receptors 
SLAMF6 (also known as Ly108), CD84, and SLAM are self-ligands differentially expressed 
in GC Tfh cells and/or GC B cells [72]. These SLAM family receptors can recruit SAP, a 
SH2-domain adaptor protein that binds to the cytoplasmic tails of SLAM family receptors 
and is specifically upregulated in GC Tfh cells [73]. SAP expression is critical for GC Tfh 
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cell development, GC development, and the generation of the majority of memory B cells 
and memory plasma cells [73-76]. In the absence of SAP, Tfh cells cannot be recruited to or 
retained in a nascent GC to maintain the GC reaction [74]. Moreover, SAP prevents binding 
of phosphatase SHP-1 to immunotyrosine switch motifs (ITSM) in SLAMF6 and provides 
positive signals within the Tfh cells [77]. These positive signals sustain T:B cell adhesion 
and helper functions.  
2.2. The functions of Tfh cells 
The most critical role of Tfh cells is their contribution to B cells for GC development 
and function. In the light zone (LZ) in GCs, GC B cells bind to the antigen and present 
antigen peptide:MHC complexes to Tfh cells, while activated Tfh cells provide help signals 
to GC B cells, essential for their survival and proliferation [9, 36]. GC B cells receive 
survival signals from Tfh cells then migrate to the dark zone (DZ), where GC B cells 
undergo proliferation and somatic hypermutation [9, 36].  
Tfh cells control GC size [47, 64, 78], regulate low-affinity B cell entry into the GC, 
support high affinity B cell occupation of the GC [79], and select high-affinity B cells during 
affinity maturation [80, 81]. Both cytokines and cell surface molecules secreted and 
presented by Tfh cells are the help signals to GC B cells. CD40L, together with IL-21 or IL-4 
is required for the GC B cells survival and proliferation [9]. CD40L-CD40 engagement is 
critical for the maintenance of GC B cells [82]. Furthermore, CD40-CD40L interaction is 
crucial for the migration of T cells into follicles [83]. IL-21 and IL-4 also trigger Ig isotype 
switching to produce IgG3, IgA and IgG1 in human B cells, or IgG1 in murine B cells [84-86] 
and IgG1 and IgE [87, 88], respectively. ICOS signal induces the expression of IL-21, IL-4, 
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c-Maf and CXCR5 [56, 89, 90]. ICOS signaling, mediated by follicular bystander B cells, is 
a key for motility of Tfh cells into B cell follicles in a Bcl-6 independent manner [60]. High 
frequency of programmed cell death ligand 1 (PD-1L) in GC B cells leads to a reduction in 
cell proliferation, activation, ICOS expression and IL-21 secretion [91].  
2.3 Tfh cell in humans 
The importance of SAP and ICOS in human Tfh cell differentiation and function was 
reported by analyzing human genetic deficiencies [9]. IL-12-STAT3/STAT4 axis is also 
associated with Tfh cell development and functions in humans [92, 93]. Recent studies have 
shown the human Tfh cell differentiation in vitro in the presence of transforming growth 
factor β (TGF-β) and IL-12 or IL-23, but not in murine CD4+ T cells [94]. Although both 
human and murine Tfh cells share many features, the mechanism of Tfh cell differentiation 
in human remains unclear.  
 Human blood memory CXCR5
+
 CD4
+
 T cells share phenotypic and functional 
properties with Tfh cells. Tfh-like cells comprise three subsets: Th1 (Tfh1), Th2 (Tfh2) and 
Th17 (Tfh17) cells [95]. A recent study from patients with adult SLE showed that while Tfh1 
cells were reduced, Tfh2 and/or Tfh17 cells were elevated among blood memory Tfh cells 
[96]. This imbalance between Tfh1 cells and Tfh2 and/or Tfh17 cells is correlated with 
disease activity correlated with disease activity, autoantibody titers and/or the frequency of 
blood plasmablasts [95-97].  
2.4. Tfh cells in autoimmune diseases 
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 High levels of class-switched autoantibodies and abnormal GC B cells are common 
symptoms in patients with autoimmune diseases [98, 99]. Recent progress has suggested the 
role of Tfh cells in the pathogenesis of autoimmune diseases. Increased frequencies of 
circulating CXCR5
+
 and PD-1
+
 or ICOS
+
  Tfh cells are found in patients with SLE [20, 22], 
Sjögren’s syndrome [97], and RA [100]. The increase of IL-21 also has been reported in the 
serum of patients with SLE [13]. Moreover, ectopic GCs formation with accumulation of T 
and B cells has been found in the kidneys of patients with lupus nephritis [101]. Thus, 
formation of tertiary lymphoid structures containing Tfh cells seems common in many 
autoimmune and inflammatory diseases [10, 102]. Furthermore, an increase of Tfh cells is 
positively correlated with autoantibody titers and symptoms and/or severity of many 
autoimmune diseases, such as SLE and RA [20-22]. That is, auto-reactive T cells, in this case 
likely Tfh cells, are the pathogenic T cells mediating the production of autoantibody and 
subsequent development of antibody-mediated autoimmune disease in humans.  
3. Follicular regulatory T cells 
 Regulatory T (Treg) cells are a subset of CD4
+
 T cells characterized by the expression 
of the transcription factor Foxp3 and are central in control immunological self-tolerance and 
homeostasis [103]. Deletion or mutation of Foxp3 in mice or humans causes multi-organ 
autoimmunity, inflammatory disease, and allergy [17]. Previous studies reported that Treg 
cells are found in B cell follicles and GCs and can suppress the B cell responses and auto-
reactive B cells [104-106]. More recently, three independent groups identified and 
characterized a new subset of Treg cells, follicular regulatory T (Tfr) cells [24-26]. Tfr cells 
are differentiated from thymus-derived Foxp3
+
 Treg cells and approximately 10~15% of 
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CXCR5
+
 CD4
+
 cells express Foxp3 [24-26]. Similar to Tfh cells, Tfr cells express Bcl-6, 
CXCR5, PD-1, ICOS, and BTLA (Figure 3). However, they do not express CD40L, IL-4, 
and IL-21. Tfr cells also express general Treg markers including Foxp3, CD25, CTLA4, 
KLRG1, GITR and IL-10 [24, 25]. In addition, Tfr cells are distinct from T-bet
+
 Treg cells 
and CD103
+
 Treg cells as they do not express CXCR5 and CD103 on their surface [24, 26]. 
Hence, Bcl6
+
CXCR5
+
Foxp3
+
 Tfr cell population represents a novel subpopulation of Treg 
cells with unique expression of transcription factors and surface molecules.  
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Figure 3. Comparison between Tfh and Tfr cells. Tfh cells express ICOS, PD-1, CD40L 
and CXCR5 on the surface; Bcl-6 and Ascl2 are known transcription factors. Like Tfh cells, 
Tfr cells express PD-1, ICOS, and CXCR5, but not CD40L. Instead, they express GITR and 
CTLA4 on the surface. Foxp3, Bcl-6 and Blimp1 are involved in the differentiation of Tfr 
cells. 
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3.1. Tfr cell differentiation and function 
Differentiation of Tfr cells depends on Bcl-6, CD28, ICOS, SAP and B cells [25, 107]. 
TNF receptor-associated factor 3 (TRAF3), Id2, Id3, and nuclear factor of activated T cells 2 
(NFAT2) are also necessary for Tfr cell differentiation [107-110]. A considerable decrease of 
Tfr cells in the CD28 and ICOS deficient mice indicates the essential role of costimulatory 
signals for Tfr cell differentiation [25, 107]. Treg-specific deletion of TRAF3 mice 
demonstrated higher GC responses and high-affinity antibodies [108]. Without changing the 
overall frequency of Treg cells, deletion of TRAF3 in Treg cells attenuated antigen-
stimulated Tfr cell production. Since TRAF3 mediates ICOS expression, loss of TRAF3 in 
Treg led to reduced expression of ICOS, which is essential for Tfr cell generation. A helix-
loop-helix family Id protein interacts with E protein and suppresses the DNA-binding activity 
of E protein [109]. Activation signaling through TCR in Treg cells decreased the expression 
of Id2 and Id3, inducing Tfr cell specific program of gene expression, including CXCR5 and 
IL-10. Recently, NFAT2 has been identified as a critical factor for the up-regulation of 
CXCR5 in thymus-derived Treg cells [110]. NFAT2 deletion in CD4
+ 
T cells or Treg cells 
led to impaired numbers of Tfr cells and enhanced GC responses, respectively.  
Blimp-1 is expressed by a certain Treg population residing in mucosal sites, which 
produces IL-10 in a Blimp-1 dependent manner [111]. Prdm1, the gene encoding Blimp-1 
and Il10 gene transcription levels were increased in Tfr cells [25]. Blimp-1-deficient mice 
demonstrated a significant increase in the frequency of Tfr cells [25]. An increase of Tfr cells 
was reported in PD-1-deficient mice, without affecting Tfr cell migration into GCs, and these 
Tfr cells possess greater suppressive ability [107]. Therefore, both Blimp-1 and PD-1 have 
２２ 
 
important roles in Tfr cell homeostasis. CTLA4 is a critical factor for controlling the GC 
reactions in both Treg and Tfr cells [112, 113]. The loss of CTLA4 on Tfr cells failed to 
suppress Tfh cells or antigen-specific antibody responses [113]. Treg cells from CXCR5, 
Bcl-6, and SAP-deficient mice show less efficiency in suppressing T cell-dependent antibody 
production in vivo [24, 25]. Therefore, Tfr cells play a fundamental role in regulating GC 
reactions. However, it is unclear how Tfr cells regulate GC reactions. One study proposed 
that Tfr cells might directly suppress B cells [24], while another study showed that Tfr cells 
suppress the differentiation of Tfh cells [25]. The current concept, how Treg and Tfr cells are 
involved in GC reaction is depicted in Figure 4. There are several unsolved questions 
remaining regarding, including 1) what is the primary mechanistic role of Tfr cells in vivo, 
and 2) do Tfr cells regulate the immune response in an antigen-specific manner [11]. 
  
２３ 
 
Figure 4. Regulatory T cells regulate B cells in the germinal center reaction in normal 
immunity. Follicular regulatory T (Tfr) cell regulates GC responses by suppressing Tfh cell 
or GC B cell.  
 
Adapted with permission from Dhaeze T, Stinissen P, Liston A, and Hellings N, Humoral 
autoimmunity: A failure of regulatory T cells? Autoimmun Rev, 2015. 
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3.2. Tfr cells in autoimmune diseases 
 The production of autoantibody is the primary feature of autoimmune disease. Most 
of self-antigen recognizing immature B lymphocytes were deleted or changed their 
specificity in the bone marrow (BM) [114]. Despite the mechanism in BM, self-reactive B 
cells can escape the negative selection in BM. However, because self-reactive T cells are 
generally deleted or anergized in the thymus and in the periphery, self-reactive B cells cannot 
get T cell help in normal condition. However, in autoimmune patients, autoreactive T cells 
are abnormally activated and lead to the activation of autoreactive B cell responses in an 
antigen-specific manner. Therefore, B cell tolerance is important for preventing emergence of 
auto-reactive B cells. However, malfunction of B cell tolerance of self-antigens leads to the 
development of autoantibodies. Various studies support that excessive Tfh responses result in 
self-reactive B cell production [115]. Many Tfr cell studies have supported the regulatory 
role of Tfr cells in Tfh cell or GC B cell reactions [116]. Therefore, a defect in Tfr cell might 
drive autoimmune diseases by elevating Tfh cell activity and generation of auto-reactive B 
cells. Lupus-like disease model using chromatin isolated from syngeneic-activated 
lymphocytes in NFAT2 mice exhibited an increase of Tfh and GC B cells, but decreased the 
frequency of Tfr cells [110]. These studies highlight the importance of Tfr cells in preventing 
loss of tolerance. BXD2 mice, one of the autoimmune disease mouse models, display a 
higher number of Tfh cells and autoantibody producing B cells, and development of 
spontaneous GCs [117, 118]. IL-21 promotes Tfh cells, but inhibits Tfr cells in BXD2 mice. 
IL-21 deficient BXD2 mice have increased the frequency of Tfr cells compared to wild-type 
BXD2 mice and transfer of Tfr cells from IL-21-deficient BXD2 mice into BXD2 mice 
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ameliorates the autoimmune phenotype of BXD2 mice [119]. There are several studies of Tfr 
cells in mice [116]. However, although the existence of human Tfr cells expressing BCL6 
and FOXP3 has been reported [120], little is known if human Tfr cells display similar 
functions as murine Tfr cells. The Tfr cell population within GC in human tonsils is much 
less abundant than in mice [115]. However, the impact or significance of this decrease is 
currently uncertain and still it is unveiled in this field.  
4. The role of CXCR5 in GC responses.  
Certain chemokines regulate chemoattraction during immunologic events, and cell 
migration is a critical factor in the development of lymphoid tissues [121]. CXCR5 is a 
member of the seven transmembrane G protein-linked receptors involved in mediating cell 
migration [121]. CXCR5 is a reliable marker for Tfh cells and the expression of CXCR5 
helps Tfh cells migrate into the B cell follicles in response to CXCL13 [39-41]. CXCR5-
deficient T cells have increased Blimp-1 expression and exhibit hampered migration into the 
B cell follicle resulting in decreased Tfh cell frequency [47, 52, 54, 122-124]. Moreover, 
constitutive expression of CXCR5 increases the follicular presence of T cells [60]. Retroviral 
constitutive expression of Ascl2 in CD4
+
 T cells induces CXCR5 expression in vitro and 
CD4
+
 T cell-specific deletion of Ascl2 decrease Tfh cells in both viral infection and 
immunization models [51]. Roles of CXCR5 in Tfr cells are also similar to those of Tfh cells. 
Transferred Treg cells from CXCR5-deficient mice were inefficient in controlling GC 
reactions and migration into the GC area [24]. NFAT2 regulates CXCR5 expression in Treg 
cells and NFAT2 deficient Tfr cells fail to ameliorate chromatin induced lupus-like disease 
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[110]. Thus, expression of CXCR5 is one of the critical events for CD4
+
 T cells to 
differentiate into Tfh or Tfr cells and migrate into B cell follicles.  
5. Animal models of antibody-mediated autoimmune lupus  
To understand the pathophysiology of autoantibody-mediated autoimmune diseases, 
researchers have developed many mouse models of autoimmune lupus, which are 
summarized in Table 4.  
Table 4. Mouse models of autoimmune lupus 
Name Target gene Autoantibody Arthritis Tfh cell Ref. 
Sanroque Rc3h1 Yes - Increased [5, 31, 32] 
NZB/W F1 - Yes - Increased [33, 34] 
BXSB-Yaa - Yes - Increased [35-37] 
MRL/lpr Fas Yes Yes 
Increased 
(extrafollicular) 
[38, 39] 
BXD2 - Yes Yes Increased [22, 40-50] 
 
5.1. Sanroque mouse animal model of autoimmune lupus 
Sanroque mice have a single amino acid mutation in the RNA-binding protein 
Roquin-1, which disturbs inducible costimulator (ICOS) repressor expression and develops 
lupus-like symptoms [125]. This single mutation in sanroque mice causes an impaired ability 
to suppress the expression of ICOS and interferon gamma (IFN-γ) and promotes Tfh cell 
generation [125, 126]. Adoptive transfer of Tfh cells from sanroque mice into wild-type mice 
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promotes spontaneous GC formation and production of autoantibodies, whereas SLAM-
associated protein (SAP) deficiency or Bcl-6 deletion in the sanroque mice prevents this 
lupus-like pathology [12].  
5.2. NZB/W F1 mouse animal model of autoimmune lupus 
The NZB/W F1 mice exhibit spontaneous lupus-like disease [127]. Like other mouse 
models, NZB/W F1 mice also exhibit increased numbers of Tfh cells and enhanced GC B 
cell responses. The lupus-like phenotype of NZB/W F1 mice is dependent on the ICOS/ICOS 
ligand (ICOSL) pathway since anti-ICOSL treatment ameliorates the disease severity by 
decreasing Tfh cells and GC B cell responses [128].  
5.3. BXSB-Yaa mouse animal model of autoimmune lupus 
BXSB-Yaa mice, which display duplication of the Tlr7 gene, also exhibit SLE-like 
phenotypes, such as spontaneous GC formation and Tfh responses [129, 130]. Unlike 
sanroque mice, SLE-like autoimmune phenotypes in BXSB-Yaa mice are dependent on IL-
21 signals [130, 131]. Deletion of the IL-21 receptor in BXSB-Yaa mice significantly 
decreases multiple parameters of SLE [130]. 
5.4. MRL/lpr mouse animal model of autoimmune lupus 
The production of autoantibodies in MRL/lpr lupus mice, which are characterized by 
deficiency of the proapoptotic molecule Fas, is from B cells in the extrafollicular foci, and 
this process is mediated by extrafollicular helper T cells [53, 132]. Bcl-6 and ICOS are 
essential for the development of extrafollicular Th cells and IL-21, and CD40L are important 
for their function [53]. 
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5.5. BXD2 mouse animal model of autoimmune lupus 
As described above, to study the pathophysiology of antibody-mediated 
autoimmunity, several animal models of experimental autoimmune lupus and arthritis have 
been developed. MRL/lpr mice spontaneously develop autoimmune lupus and arthritis [133]. 
However, the deficiency of the Fas gene is not common in patients with lupus. NZB/W F1 
mice are another autoimmune lupus model which also spontaneously develops autoimmune 
lupus phenotypes [127]. However, this strain does not develop arthritis symptoms, which are 
common in patients with lupus. In this regard, BXD2 mice represent an alternative animal 
model to study the complex features of antibody-mediated autoimmune diseases that more 
closely mimic the pathophysiology of autoantibody-mediated diseases in humans.  
BXD2 is a recombinant inbred strain established by intercrossing the F2 generation of 
C57BL/6 and DBA/2J strains for more than 20 generations [134, 135]. BXD2 mice 
excessively produce rheumatoid factor and autoantibodies and spontaneously erosive arthritis 
as well as autoimmune lupus symptoms including glomerulonephritis [118, 136-138]. 
Genetic linkage analysis revealed that BXD2 mice have several autoimmune loci such as 
Lbw, Sle, Sles, Lmb and Asm2 as a result of complicated interaction of multiple genes from 
the original parental B6 and DBA/2 mice [118]. In addition, increased expression of CD28 in 
CD4
+
 T cells of BXD2 mice can induce the expansion of CD86
+
 GC B cells and the 
expression of activation-induced cytidine deaminase (AID) in B cells [138]. These multiple 
genetic and immunologic characters together seem to enhance spontaneous autoimmune 
phenotypes in BXD2 mice, thereby providing a novel animal tool to study the mechanism of 
naturally occurring autoimmune GC responses.  
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A series of studies done by Mountz and colleagues have demonstrated the role of IL-
17 in developing spontaneous GC formation and autoantibody-mediated autoimmune 
phenotypes in the BXD2 mice [117, 139, 140]. In their works, IL-17 was shown to induce the 
expression of regulator of G-protein signaling (RGS) proteins on B cells and these RGS 
proteins stabilized the interaction of the germinal center B cells with nearby T cells [117, 
139]. Without affecting the total number of Tfh cells and their function in vitro, IL-17 was 
indicated to play a critical role in the localization of Tfh cells in the GC light zone in BXD2 
mice [140]. A recent study also showed that an increased level of IL-21 is associated with the 
development of autoimmune diseases [141]. In BXD2 mice, IL-21 plays a critical role in 
developing spontaneous GC formation and autoimmune pathophysiology [140]. The high 
level of IL-21 in BXD2 mice upregulates Tfh cell differentiation but suppresses Tfr cell 
development and functions [119]. 
6. Overall hypothesis and specific aims 
 Abnormalities of Tfh cells are strongly correlated with many autoimmune diseases. 
Currently, many immunosuppressive therapies have been developed and used to treat 
autoimmune diseases. Nevertheless, these reagents have significant disadvantages including 
systemic immune suppression and only partial target-specificity. Therefore, the main goal of 
the present dissertation is to develop a new therapy for auto-reactive B cell responses by 
regulating Tfh cell-mediated GC responses. Expression of CXCR5 on Foxp3
+
 regulatory T 
cells enables cells to migrate into GC zone and these Tfr cells specifically regulate GC 
reactions in vivo. In addition, loss of Tfr cells leads to autoimmune diseases. Although Tfr 
cells are a good candidate for the treatment of auto-reactive B cell responses, their low 
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frequency and unknown stability are possible drawbacks in the development of Tfr cell-based 
immunotherapy. We selected BXD2 mice as our model system to examine the therapeutic 
potential of Tfr cells for the treatment of autoimmune diseases. 
Our overall hypothesis is that the development of auto-reactive B cell responses is 
mediated by Tfh cells, and that, adoptive transfer of Tfr cells will ameliorate the development 
of autoantibodies in autoimmune prone-hosts by inhibiting autoimmune B cell responses. For 
this purpose, in Chapter 2, we have investigated the role of Tfh cells in the auto-reactive B 
cell responses in BXD2 mice. We also hypothesized that retroviral transduction of CXCR5 
onto Foxp3
+
 Treg cells will enable these cells to control GC reactions. In Chapter 3, we have 
tested this hypothesis by determining whether adoptively transferred CXCR5 overexpressing 
Treg cells will inhibit GC responses.  
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Regulation of Autoimmune Germinal Center Reactions in Lupus-Prone  
BXD2 Mice by Follicular Helper T cells 
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1 Rationale and Hypothesis 
 Tfh cell responses are essential for the generation of effective humoral immune 
responses against infectious agents [9]. By contrast, excessive Tfh cell responses to self-
antigens are shown to be associated with antibody-mediated autoimmune diseases, such as 
SLE, RA, Sjögren syndrome, and juvenile dermatomyositis [12, 13]. Among multiple animal 
models of experimental autoimmune lupus and arthritis, BXD2 mice provide many 
advantages since they spontaneously develop autoimmune lupus, arthritis and subsequent 
glomerulonephritis without Fas deficiency [142].  Therefore, BXD2 mice offer a novel and 
robust animal model to study comprehensively the pathophysiology of antibody-mediated 
autoimmunity. A series of studies by one laboratory have shown a critical contribution of IL-
17 and Th17 cells in mediating autoimmune B cell responses in these mice [117, 140]. 
Moreover, Th17 cells were found to reside in spontaneous GCs and IL-17 enhanced the 
formation of GCs in BXD2 mice. In addition, IL-17 did not affect the total number of Tfh 
cells or their function in vitro, whereas IL-17RA-deficient Tfh cells in BXD2 mice were 
shown to be impaired in their ability to localize to the GC LZ. Although Th17-related 
phenotypes of BXD2 mice were characterized in these initial studies, the contribution of Tfh 
cells to auto-reactive B cell responses in this autoimmune strain was not fully elucidated.  
We hypothesized here that the role of Tfh cells in BXD2 mice is critical for 
autoantibody-mediated autoimmunity. We found that both the frequency of Th17 cells and 
the levels of IL-17 in the circulation of BXD2 mice were comparable to those of wild-type. 
On the other hand, the frequency of Tfh cells was increased in BXD2 mice while the 
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frequency of Tfr cells was reduced. Also, the frequency of Tfh cells was positively correlated 
with the GC reaction factors. Lastly, we found that IL-21 secreting Tfh cells are greatly 
responsible for regulating autoimmune GC reactions in BXD2 mice. Our findings indicate 
that Tfh cells rather than Th17 cells are the major contributors to the autoimmune GC 
reactions in BXD2 mice. 
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2 Results 
2.1. Spontaneous germinal center reactions in BXD2 mice 
 As a first step to determine the contribution of each Th cell response to autoimmune 
lupus in BXD2 mice, we comparatively analyzed the production of autoantibodies and the 
generation of spontaneous germinal center reactions between BXD2 mice and C57BL/6 
(wild-type, WT) control mice at the age of 6 months or older. Consistent with previous 
reports [117, 118, 137, 140], we observed that the levels of autoantibodies to double-stranded 
DNA and histone in the sera of BXD2 mice were significantly higher than those in control 
mice (Figure 5A). Similarly, we also observed spontaneous generation of GCs in the BXD2 
mice (Figure 5B and 5C), which was associated with increased frequency and number of 
GL7
+
Fas
+
 germinal center B cells in the spleens (Figure 6A). Increased autoantibodies and 
spontaneous GCs were observed as early as 3 months of age in the BXD2 mice (data not 
shown). However, the frequency of GL7
+
Fas
+
 germinal center B cells remained comparable 
between the two groups in other secondary lymphoid organs, such as peripheral lymph nodes 
and Peyer’s patches (Figure 6B). 
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Figure 5. Spontaneous germinal center responses in BXD2 mice. (A) Auto-reactive 
autoantibody levels against double-strand DNA and histone in the sera of WT and BXD2 
mice at the age of 6 months or older were measured by ELISA. (B) Immunofluorescence 
imaging of PNA
+
 (red) germinal center area of the spleen from WT control or BXD2 mice 
(×4 magnification). (C) The number of GC per spleen section in the WT and BXD2 mice was 
enumerated by fluorescence microscopy. Data are represented as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 6. Spontaneous germinal center B cell development in BXD2 mice. 
(A) Flow cytometry analysis of the percentage and number of GL7
+
Fas
+
 germinal center B 
cells in the WT and BXD2 mice at the age of 6 months or older. (B) Flow cytometry analysis 
of GL7
+
Fas
+ 
germinal center B cells in the indicated lymphoid organs from WT and BXD2 
mice (iLN: inguinal lymph node, aLN: axillary lymph node, mLN: mesenteric lymph node, 
PP: Peyer’s patch). Cells were gated on B220+ B cells. Data are represented as mean ± SEM. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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2.2. Analysis of helper T cell subsets in BXD2 mice 
We next analyzed each helper T cell subset in the spleens of BXD2 mice. The 
frequency of IFN-γ-producing Th1 cells was slightly but significantly higher in the spleens of 
BXD2 mice compared to control mice (Figure 7A). In addition, due to increased cellularity in 
the spleens of BXD2 mice, the absolute number of Th1 cells was remarkably higher in this 
group. The proportion of Th1 cells were increased in most of the secondary lymphoid organs 
of BXD2 mice, except Peyer’s patches (Figure 7B). However, unlike previous study [117], 
we observed that the frequency of IL-17-producing Th17 cells in the spleens of BXD2 mice 
was comparable to that of control mice, although the absolute number of Th17 cells appeared 
to be increased in the former group (Figure 8A). Similarly, the frequency of IL-17 secreting 
cells in total splenocytes of BXD2 mice was comparable to that of control mice, ruling out 
any increased production of IL-17 from non-CD4
+
 T cell population (Figure 7C). Despite the 
increased number of Th17 cells, the levels of IL-17 in the circulation of BXD2 mice were 
comparable to that of control mice (Figure 8A). To further characterize the Th1 and Th17 
cell responses, we analyzed the expression of Th1 and Th17-associated genes by using 
quantitative RT-PCR. As depicted in Figure 7B, we observed that the levels of Il17a and 
Rorc mRNA expression in the spleens of BXD2 mice were comparable to those of control 
mice, while the levels of Tbx21 (encoding T-bet in mouse) and Ifng were increased in the 
BXD2 mice. Commensal bacteria such as segmented filamentous bacteria (SFB) can 
modulate Th17 cell responses [143, 144]. To test if any differences of gut microbiota 
between BXD2 and control mice impact Th17 responses, we co-housed BXD2 mice with 
control mice for 4 weeks. The frequencies of Th17 cells in both Peyer’s patches and 
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mesenteric lymph nodes were comparable between the two groups (Figure 9). These results 
together demonstrate that Th17 cell response in BXD2 mice did not significantly differ from 
control mice in steady state.  
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Figure 7. Th17 cells are not a major subset of T helper cells in BXD2 mice. (A) Flow 
cytometry analysis of the percentage and number of IFN-γ or IL-17A positive CD4+ T cells 
in the spleen from WT and BXD2 mice at the age of 6 months or older. (B) Flow cytometry 
analysis of IFN-γ+ Th1 or IL-17A+ Th17 cells in the indicated lymphoid organs from WT and 
BXD2 mice (iLN: inguinal lymph node, aLN: axillary lymph node, mLN: mesenteric lymph 
node, PP: Peyer’s patch). (C) Frequency of IFN-γ+ or IL-17A+ cells in whole splenocytes of 
WT and BXD2 mice. Data are representative of the analysis indicate mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001 compared with BXD2-WT mice. 
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Figure 8. IL-17 in circulation and Th17 related gene expressions are not increased in 
BXD2 mice. (A) IL-17A levels in the sera of WT and BXD2 mice at the age of 6 months or 
older were measured by ELISA. (B) Quantitative RT-PCR analysis of Th1 or Th17 cell 
related genes from WT and BXD2 mice splenocytes at the age of 6 months or older. Data are 
representative of the analysis indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
compared with BXD2-WT mice. 
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Figure 9. The gap of Th17 cells in BXD2 mice is not due to the difference of gut 
microenvironment. Percentage of Th17 cells in the mesenteric lymph nodes and Peyer’s 
patches from co-housed WT and BXD2 mice. Data are representative of the analysis indicate 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with BXD2-WT mice. 
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2.3. Analysis of Tfh and Tfr cells in BXD2 mice 
Since increased Tfh cells are associated with systemic autoimmune diseases [22, 145, 
146], we next analyzed Tfh cell responses in the BXD2 mice. As shown in Figure 10A, the 
frequency and number of PD1
+
CXCR5
+
 Tfh cells were significantly higher in the spleens of 
BXD2 mice compared to control mice. Moreover, the levels of Tfh cell signature genes, such 
as Il6, Il21, Bcl6, Pdcd1 (encoding PD-1) and Icos were all significantly increased in the 
splenocytes of BXD2 mice compared with those in control mice (Figure 10B). The frequency 
of Tfh cells in the other secondary lymphoid organs, except axillary lymph node and Peyer’s 
patches, remained comparable between BXD2 and wild-type mice (Figure 10C). 
Extrafollicular T helper cells are proposed to be involved in the development of antibody-
mediated autoimmunity [53]. However, the frequency of PD-1
low
 extrafollicular T helper 
cells in BXD2 mice remained comparable to that of control mice (Figure 11A and 11B). 
Collectively, these results demonstrate that the spleens of BXD2 mice contained significantly 
increased Tfh cells and, to a lesser extent, Th1 cells, while the frequencies of Th17 cells and 
PD-1
low
 extrafollicular T helper cells were similar when compared with control mice. 
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Figure 10. Tfh cell responses are increased in the BXD2 mice. (A) Flow cytometry 
analysis of the percentage and number of PD-1
+
CXCR5
+
 CD4
+
 T cells in the spleens of WT 
and BXD2 mice at the age of 6 months or older. (B) Quantitative RT-PCR analysis of Tfh 
cell related genes from WT and BXD2 mouse splenocytes at the age of 6 months or older. (C) 
Flow cytometry analysis of the percentage and number of PD-1
+
CXCR5
+
 CD4
+
 T cells in the 
indicated lymphoid organs from WT and BXD2 mice (iLN: inguinal lymph node, aLN: 
axillary lymph node, mLN: mesenteric lymph node, PP: Peyer’s patch). Data are represented 
as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 11. The frequency of extrafollicular T helper cells is similar between WT and 
BXD2 mice. (A) Flow cytometry analysis of PD-1
low
CXCR5
+
 CD4
+
 T cells in the spleens of 
WT and BXD2 mice at the age of 3 months. (B) Flow cytometry analysis of PD-
1
low
CXCR4
+
CXCR5
-
 CD4
+
 T cells in the spleens of WT and BXD2 mice at the age of 3 to 4 
months. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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PD1
+
CXCR5
+
Foxp3
+
 Tfr cells have emerged as a specialized subset of regulatory T 
cells suppressing germinal center reactions in vivo [24-26]. Therefore, we determined if the 
frequency of Tfr cells, as well as the ratio of Tfh cells and germinal center B cells per Tfr cell 
in the BXD2 mice, differed from that of control mice. Although the frequency of total 
Foxp3
+
 T cells was found to be higher in BXD2 mice than control mice (Figure 12A), we 
observed that the frequency of Tfr cells was slightly but significantly lower in the spleens of 
the former group (Figure 12B). The absolute number of Tfr cells, however, was higher in the 
spleens of BXD2 mice due to increased spleen cellularity (Figure 12B). As shown in Figure 4, 
5 and 9, the numbers of germinal centers, germinal center B cells and Tfh cells were all 
significantly increased in the BXD2 mice. Accordingly, the ratio of germinal center B cells 
per Tfr cell was significantly higher in BXD2 mice than control mice (Figure 12C). Similarly, 
the ratio of Tfh cells per Tfr cell was also significantly greater in the former group (Figure 
12C). 
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Figure 12. The ratio of Tfh/Tfr cells is increased in the BXD2 mice. (A) Flow cytometry 
analysis of the percentage and number of CD4
+
Foxp3
+
PD-1
+
CXCR5
+
 Tfr cells in the spleens 
of WT and BXD2 mice at the age of 6 months or older. (B) The percentage and absolute 
number of Foxp3
+
 CD4
+
 T cells in the spleens of WT and BXD2 mice. (C) The ratio of 
Foxp3
-
 Tfh cells to FoxP3
+
 Tfr cells in the mouse spleens and germinal center B cells to 
FoxP3
+
 Tfr cells in the mouse spleen. Data are represented as mean ± SEM. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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2.4. Correlation analysis between autoantibodies, germinal center B cells, Th17 and Tfh 
cells in BXD2 mice 
 Our results in Figure 7 to 11 showed no evident increase in Th17 cell responses in 
BXD2 mice, which are contradictory to previous studies of another group [117, 140, 147], 
suggesting that Th17 cell responses might not be associated with increased autoantibodies in 
the BXD2 mice. To address this possibility, we examined whether the levels of 
autoantibodies and the frequencies of germinal center B cells are correlated with the 
frequencies of Th17 or Tfh cells. Linear regression analysis showed no correlation between 
the frequencies of Th17 cells and those of germinal center B cells (Figure 13A). Similarly, no 
correlation was observed between the frequencies of Th17 cells and the levels of anti-dsDNA 
(Figure 13B) or between the numbers of Th17 cells and germinal center B cells (Figure 13C). 
In sharp contrast, both the frequencies of germinal center B cells and the levels of anti-
dsDNA showed a clear positive correlation with the frequencies of Tfh cells (Figure 14A and 
14B). Moreover, a strong correlation was observed between the number of Tfh cells and 
those of germinal center B cells (Figure 14C). In addition, the frequencies of Th1 cells 
appeared to be, with a lesser extent, also positively correlated with those of germinal center B 
cells and the levels of anti-dsDNA (Figure 15A and 15B). As expected, the levels of anti-
dsDNA showed strong positive correlation with the frequencies of germinal center B cells 
(Figure 15C), while the frequencies of Tfr cells showed no correlation with those of germinal 
center B cells (Figure 15D). Together, these linear regression analyses clearly demonstrate 
Tfh cell responses, but not Th17 cell responses, showed a strong positive correlation with 
auto-reactive germinal center B cell responses in the BXD2 mice.  
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Figure 13. Th17 cells do not correlate with outputs of GC responses in BXD2 mice. 
Linear regression analysis of the frequency of Th17 cells (A) with that of germinal center B 
cells, and Th17 cells (B) with dsDNA specific autoantibody levels. Linear regression analysis 
of the number of Th17 cells (C) with that of germinal center B cells. Pearson correlation 
coefficients (r
2
) between the percent of T helper cell subset and germinal center B cells or 
those of T helper cell subset and dsDNA specific autoantibodies levels are indicated in each 
graph. 
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Figure 14. Tfh cells positively correlate with outputs of GC responses in BXD2 mice. 
Linear regression analysis of the frequency of Tfh cells (A) with that of germinal center B 
cells, and Tfh cells (B) with dsDNA specific autoantibody levels. Linear regression analysis 
of the number of Tfh cells (C) with that of germinal center B cells. Pearson correlation 
coefficients (r
2
) between the percent of T helper cell subset and germinal center B cells or 
those of T helper cell subset and dsDNA specific autoantibodies levels are indicated in each 
graph. 
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Figure 15. Linear regression analysis between Th1/Tfr cells and germinal center B cells. 
Linear regression analysis of the frequency of Th1 cells with GC B cells (A), Th1 cells with 
dsDNA specific autoantibody levels (B), Linear regression analysis of germinal center B 
cells with dsDNA specific autoantibody levels (C), the frequency of Tfr cells with germinal 
center B cells (D). Pearson correlation coefficients (r
2
) between the percent of T indicated 
helper T cell subset and of germinal center B cells or those of Th1 cells or GC B cells and 
dsDNA specific autoantibodies levels are indicated at each graph. 
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2.5. CXCR5
+
CD4
+
 T cells, but not CCR6
+
CD4
+
 T cells, from BXD2 mice induce IgG 
production from naïve B cells in an IL-21-dependent, IL-17-independent manner 
Although previous studies described a critical contribution of Th17 cell responses to 
the generation of autoimmune B cell responses in BXD2 mice, our findings showed no 
evident correlation between Th17 cells and autoantibody responses. To further determine the 
contribution of Th17 cells and Tfh cells to the generation of spontaneous germinal center B 
cell responses in the BXD2 mice, we sought to determine whether Th17 cells and Tfh cells 
isolated from BXD2 mice can trigger IgG production from naïve B cells. Expression of 
CCR6 and CXCR5 on CD4
+
 T cells are reliable markers of Th17 and Tfh cells, respectively 
[9, 148, 149]. Hence, we purified CCR6
+
CD4
+
 T cells and CXCR5
+
CD4
+
 T cells from the 
spleens of 3~9 month-old BXD2 mice (Figure 16A). When re-stimulated with these cells, 
purified CXCR5
+
 and CCR6
+
 cells almost exclusively expressed IL-21 and IL-17, 
respectively (Figure 16A). Th17 cells are known to express IL-21 [150]; however, 
CCR6
+
CD4
+
 T cells from the BXD2 mice showed little expression of IL-21. Moreover, few 
CXCR5
+
CD4
+
 T cells from the BXD2 mice expressed IL-17 (Figure 16A). Consistent with 
these results, quantitative RT-PCR analysis showed that the CXCR5
+
 population expressed 
significantly higher levels of Il21, Bcl6 and Ascl2 mRNA, while the CCR6
+
 population 
expressed higher levels of Il17a and Rorc (Figure 16B). These results demonstrate the 
purified CCR6
+
 and CXCR5
+
 populations among the CD4
+
 T cells represented Th17 cells 
and Tfh cells in the BXD2 mice. To determine the role of each CD4
+
 T cell subset from the 
BXD2 mice on the activation and differentiation of B cells, the purified T cells were cultured 
with B220
+
GL7
-
IgD
+
 naïve B cells isolated from BXD2 mice in the presence of anti-CD3 
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and anti-IgM for 7 days. As depicted in Figure 17A, we found that CXCR5
+
CD4
+
 T cells 
efficiently stimulated B cells to produce IgG even when the lower number of T cells was 
used (B:T cell ratio = 10:5). By contrast, CCR6
+
CD4
+
 T cells failed to do so, even when a 
higher number of T cells was used (B:T cell ratio = 10:10) (Figure 17A). To test the role of 
each helper T cell population on B cell expansion, we labeled B cells with CFSE before co-
culturing them with T cells. The addition of CXCR5
+
 CD4
+
 T cells induced significant B cell 
proliferation while CCR6
+
 CD4
+
 T cells failed to do so (Figure 17B). Similarly, the addition 
of Th17 cells differentiated in vitro from naïve BXD2 T cells did not induce IgG production 
from co-cultured naïve B cells in our experimental setting (Figure 18A and 18B). To 
determine the role of IL-17 and IL-21 in this process, anti-IL-17 or IL-21R-Fc fusion protein 
was added into the culture. As shown in Figure 19, the addition of IL-21R-Fc almost 
completely abolished the production of IgG from naïve B cells co-cultured with 
CXCR5
+
CD4
+
 T cells of BXD2 mice, while the addition of anti-IL-17 showed no effect. 
These results strongly suggest that CXCR5
+
CD4
+
 T cells in the BXD2 mice were responsible 
for the enhanced autoantibodies and germinal center B cell responses through an IL-21 
dependent, IL-17-independent mechanism, while CCR6
+
CD4
+
 T cells played little role in the 
activation of auto-reactive B cells in BXD2 mice in our experimental setting. 
 
  
５３ 
 
Figure 16. Isolated CXCR5
+
CD4
+
 and CCR6
+
CD4
+
 T cells from BXD2 mice present 
characteristics of Tfh-like and Th17 like cells, respectively. (A) CXCR5
+
 CD4
+
 T cells 
and CCR6
+
 CD4
+
 T cells were sorted and subjected to intracellular cytokine staining. (B) 
Quantitative RT-PCR analysis of Tfh or Th17 cell-related gene expression in the CXCR5
+
 
and CCR6
+
 CD4
+
 T cells from BXD2 mice. Data are represented as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 17. IL-21-producing CXCR5
+
CD4
+
 T cells of BXD2 mice, but not IL-17-
producing CCR6
+
CD4
+
 T cells, provide B cell help for IgG production. (A) Naïve B cells 
(B220
+
IgD
+
GL7
-
) from BXD2 mice were co-cultured with CXCR5
+
 or CCR6
+
 CD4
+
 T cells 
from BXD2 mice for 7days. The total IgG levels were measured by ELISA. (B) The 
proliferation of CFSE labeled naïve B cells (B220
+
IgD
+
GL7
-
) from BXD2 mice obtained 
from (A) and determined by flow cytometry. Data are represented as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001, ###p < 0.001 comparing 10:10–10:5 ratio of B:T co-culture 
condition. 
 
  
５５ 
 
Figure 18. In vitro differentiated Th17 cells do not provide B cell help for IgG 
production. (A) Cytokines expression in in vitro differentiated Th17 cells 5 days after 
stimulation from naïve (CD4
+
CD25
-
CD44
-
CD62L
+
) CD4
+
 T cells of BXD2 mice. (B) Naïve 
B cells (B220
+
IgD
+
GL7
-
) from BXD2 were co-cultured with in vitro differentiated Th17 
cells described in (A) for 7 days and the levels of total IgG were measured by ELISA. Data 
are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 19. Blocking IL-21 signals in IL-21-producing CXCR5
+
CD4
+
 T cells of BXD2 
mice hampers the IgG. Different cytokine blocking reagents, isotype control antibody (Iso 
Hu-Fc), Rat anti-mouse IL-17A antibody (α-IL-17A), or recombinant mouse IL-21 receptor 
Fc chimera (IL-21R-Fc) were added (10 μg/ml, every other day) into the cell culture 
described in Figure 15 and the levels of total IgG were measured by ELISA. Data are 
represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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3. Discussion 
 The role of Tfh cells and Th17 cells in the development of antibody-mediated 
autoimmune diseases such as lupus and arthritis has remained poorly understood. In this 
chapter, we sought to determine the correlation and contribution of Tfh and Th17 cells in the 
development of auto-reactive autoimmune B cell responses in the BXD2 mouse model of 
lupus. The role of IL-17 in the auto-reactive autoimmune B cell responses has been 
previously examined in the BXD2 animal model of lupus. The levels of IL-17 in the 
circulation and the frequency of Th17 cells in the spleen were shown to be elevated in the 
BXD2 mice [117]. The increased IL-17 enhanced the B cell chemotactic ability and 
stabilized the interaction of the germinal center B cells with nearby T cells [117, 139]. IL-17 
also promoted the localization of Tfh cells in GC, but not the frequency and function of Tfh 
cells [140]. In contrast to these findings, our results demonstrated that Tfh cells are strongly 
associated with increased autoimmune B cell responses while Th17 cells play only a minor 
role in this process [142]. There were no clear differences in the IL-17 or Th17 cell related 
phenotypes; frequencies, genes expression levels, and protein level, between BXD2 mice and 
WT control mice (Figure 7 and 8). While the frequency of Tfh cells, the ratio of Tfh cells per 
Tfr cell, and Tfh related gene expression were all increased in BXD2 mice compared to 
control mice (Figure 10, 11 and 12). Using a co-culture system, we clearly demonstrated that 
IL-21, from Tfh-like cells (CXCR5
+
CD4
+
 T cells) rather than IL-17, from Th17-like cells 
(CCR6
+
CD4
+
 T cells) was essential for activating the production of IgG from naïve B cells 
(Figure 16 to 18). Thus, Tfh cells are responsible for the augmented autoantibodies and 
germinal center B cell responses through an IL-21 dependent mechanism in BXD2 mice.  
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Although the frequency of Tfh cells was increased in the BXD2 mice, the frequency 
of Tfr cells in the same mice were lower than that in control mice (Figure 10 and 12). In 
addition, the ratio of germinal center B cells per Tfr cell or Tfh cells per Tfr cell were all 
significantly increased in the BXD2 mice (Figure 12). As a consequence, spontaneous 
germinal center reactions and subsequent development of a lupus phenotype in this strain 
appeared due to decreased numbers of Tfr cells. A recent study showed that adoptive transfer 
of Tfr cells into young BXD2 mice decreased GC formation and reduced the number of 
autoantibody-producing B cells [119]. Therefore, transfer of Tfr cells might be a useful 
therapeutic approach for the treatment of autoimmune diseases. However, acquiring 
sufficient numbers of Tfr cells for this approach will be difficult. Alternative approaches that 
would provide similar results as transfer of Tfr cells may need to be developed. This issue 
will be addressed in Chapter 3.  
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CHAPTER 3 
 
 
 
Application of Tfr like Cells for the Regulation of Auto-reactive B cell-mediated  
Autoimmune Disease Mouse Models 
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1 Rationale and Hypothesis 
 In chapter 2, we demonstrated that Tfh cells are integrally involved in the 
pathophysiology of auto-reactive autoimmunity in the BXD2 mouse model. Production of 
autoantibodies to self-antigen is a hallmark of variable autoimmune diseases such as SLE or 
RA or MS. Therefore, the regulatory mechanism is a precondition for preventing loss of self-
tolerance in GC and autoantibody production.  
Recent studies have identified Bcl-6
+
CXCR5
+
Foxp3
+
 Tfr cells, a distinct subset of 
Treg cells [24-26]. Tfr cells share both Tfh cells (Bcl-6, CXCR5, PD-1, and ICOS) and Treg 
cells (GITR, CTLA4, CD25, and Blimp-1) features and are specialized to suppress GC 
reactions in vivo. Although several groups have studied Tfr cells, the exact mechanisms by 
which Tfr cells inhibit GC B cell responses remain to be explored [116]. Due to their ability 
to specifically suppress GC B cell responses with little suppression of the other arms of 
adaptive immunity, the use of Tfr cells has been proposed as a novel approach for the 
treatment of autoantibody-mediated autoimmune diseases. However, the low frequency of 
the Tfr population has posed a major obstacle for the assessment of Tfr cells as a therapeutic 
for autoimmune disease.  
For GC reaction, both Tfh cells and Tfr cells have to migrate to the B cell follicle. 
CXCR5-mediated migration of Tfr cells into B cell zone appears to be essential for their 
functional specificity [24]. As described above, Tfr cells share Treg cells properties and 
expression of CXCR5 and CXCR5-mediated migration into the B cell zone seem to be 
crucial for Tfr cell function. For these reasons, we hypothesized that the generation of Tfr-
like cells by engineering Treg cells to express CXCR5, termed as ‘engineered Tfr cell (eTfr 
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cell)’ would endow the eTfr cells to function as Tfr cells in vivo. Overexpression of CXCR5 
on helper T cells has already been shown to increase the number of CD4
+
 T cells in the 
follicle [60]. Therefore, we hypothesize that adoptively transferred CXCR5-transduced Treg 
cells would modulate humoral immune responses.  
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2. Results 
2.1. Generation of CXCR5 expressing Treg cells 
 Recent studies identified CXCR5
+
Foxp3
+ 
Treg cell subset, termed as Tfr cell, which 
specifically suppresses GC responses [24-26]. Previous studies have demonstrated the 
existence of Treg cells in the B cell follicles and GCs [104]. Treg cells also directly suppress 
B cell responses and auto-reactive B cells [105, 106]. Therefore, we hypothesized that 
adoptively transferred Foxp3
+
 Treg cells which were retrovirally transduced with CXCR5 
would migrate to germinal center B cell zones and impair the autoimmune humoral immune 
response. 
To test this hypothesis, we first cloned mouse CXCR5 into a retroviral vector (RV) 
containing IRES and GFP. We transduced control RV-GFP or CXCR5-RV-GFP vector into 
Treg cells from Foxp3-IRES-mRFP (FIR) reporter mice, which expresses RFP in Foxp3
+
 T 
cells. Thereafter, we call control RV-GFP transduce Treg cells as Control-transduced Treg 
and CXCR5-RV-GFP transduced Treg cells as CXCR5-transduced Treg cells. After five 
days of ex vivo expansion of Treg cells, GFP and RFP double positive cells were purified by 
flow cytometry (Figure 20A). First, we examined the CXCR5 expression on RV-transduced 
Treg cells. Figure 20B confirms that transduction with CXCR5-RV-GFP successfully 
induced the expression of CXCR5 on the surface of Treg cells. We next assessed whether 
CXCR5 overexpression affects the gene expression profile of the transduced Treg cells. 
Except in the case of the Cxcr5 gene, expression levels of other genes related to either Tfh or 
Treg cells, were not affected following transduction  (Figure 21). Therefore, overexpression 
of CXCR5 on Foxp3
+
 Treg cells did  not affect any off-target gene expression profiles.   
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Figure 20. Generation of CXCR5 overexpressing Treg cells. (A) Sorting strategy of 
isolating RV-transduced Treg cells. Treg cells from RFP-IRES-Foxp3 (RIF) mice were 
transduced by control-GFP or CXCR5-GFP retroviral vector. After 5 days of ex vivo 
expansion, CD4
+
GFP
+
RFP
+
 cells were sorted by flow cytometry. (B) Flow cytometry 
analysis of CXCR5 expression from (A).  
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Figure 21. Retroviral transduction of CXCR5 on Treg cells does not change the Treg 
genes expression profiles. Quantitative RT-PCR analysis of Tfh cell and Treg cell related 
genes from Control or CXCR5-transduced Treg cells. Data are represented as mean ± SEM. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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2.2. Functional analysis of CXCR5-transduced Treg cells in vitro 
 We observed that there were no critical gene expression profile changes in CXCR5-
transduced Treg cells other than Cxcr5 gene. We then addressed whether CXCR5 
overexpression affects the suppressive role of Treg cells. To examine the suppressive 
function in RV-transduced Treg cells, we performed an in vitro Treg suppression assay. 
Conventional CD4
+
 T responder cells (Tresp) were stained with proliferation dye (eFlour670) 
and cultured with CD4
+
 T cell-depleted splenocytes plus either Control or CXCR5-
transduced Treg cells at different ratios. We found no difference between Control and 
CXCR5-transduced Treg cell’s suppressive capacity (Figure 22). Thus, overexpression of 
CXCR5 on Treg cells does not affect Treg cell’s suppressive function.  
We next examined whether the CXCR5 overexpressed on the Treg cells is functional. 
CXCL13 is the known ligand for CXCR5 and is critical for B cell homing to follicles and 
formation of GC [151]. To determine whether CXCR5-transduced Treg cells respond to 
CXCL13, we employed an in vitro chemotaxis assay (cell migration assay) using a transwell 
system (Figure 23). Control-transduced Treg cells migrated into the bottom well at a minimal 
level (around 10% of input cells). However, CXCR5-transduced Treg cells successfully 
migrated into the bottom well at a much higher level. As CXCL13 concentration was 
increased, the migration of the CXCR5-transduced Treg cells increased. Thus, 
overexpression of CXCR5 on Treg cells enabled them to migrate in response to CXCL13 
while not affecting their gene expression profile or their ability to suppress conventional CD4 
responder proliferation. 
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Figure 22. CXCR5-transduced Treg cells do not lose their suppressive ability. Analysis 
of cell proliferation dye-labeled responder T cells (Tresp, CD4
+
CD25
-
 T cell). Tresp cells and 
Control or CXCR5-transduced Treg cells were co-cultured with anti-CD3 and irradiated T 
cell-depleted splenocytes for 3 days. Cell proliferation was measured by flow cytometry. The 
results shown are representative of three independent experiments. 
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Figure 23. CXCR5-transduced Treg cells can migrate in a CXCL13 dependent manner. 
Transwell migration assay of Control and CXCR5-transduced Treg cells in the presence of 
CXCL13. CXCR5-transduced Treg cells migrated dependent on CXCL13 concentration. The 
results shown are representative of three independent experiments. Data are represented as 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared with different concentration of 
CXCL13 in the same group. #p < 0.05, ##p < 0.01, ###p < 0.001 compared with Control and 
CXCR5-transduced Treg cell in the same concentration of CXCL13.  
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2.3. Functional analysis of CXCR5-transduced Treg cells in vivo 
As shown in previous experiments, CXCR5-transduced Treg cells have both 
suppressive and migratory capacity in vitro. We next sought to determine whether these 
transduced cells would migrate into the GC area and their ability to suppress a GC response 
in vivo. It was reported previously that CXCR5 overexpressing conventional CD4
+
 T cells 
from Ovalbumin (OVA) specific TCR receptor (OT-II) expressing mice preferentially 
migrated into B cell follicles compared to control-RV transduced OT-II cells [60]. 
Additionally, lentivirally transduced CXCR5 on thymus-derived natural Treg (nTreg) cells 
from CD4
+
 T cell specific NFAT2 deficient mice rescued Tfr cell-mediated function in vivo 
[110]. Therefore, we expected that CXCR5-transduced Treg cells will migrate to the GC area 
and regulate GC responses in vivo.  
To verify in vivo function of CXCR5-transduced Treg cells, we designed adoptive co-
transfer experiment based on previous publications [107, 152]. Tfh cells from 4-hydroxy-3-
nitrophenylacetyl-conjugated keyhole limpet hemocyanin (NP-KLH) immunized B6SJL 
congenic mice (CD45.1) and RV-infected Treg cells were transferred into TCRβ-deficient 
mice (Figure 24). Due to the lack of TCR signals, TCRβ-deficient mice do not have T cells. 
Therefore, this approach allowed us to determine if Tfh cells and CXCR5 overexpressing 
Treg cells could functionally regulate GC responses separately from differentiation [107]. 
We adoptively co-transferred FACS sorted 50,000 of Tfh cells from NP-KLH immunized 
B6SJL mice and 25,000 of Control or CXCR5-transduced Treg cells into TCRβ KO mice. 
We subcutaneously immunized recipient mice 1 day later with NP-KLH and analyzed GC 
reactions and titers of NP-specific IgG and IgM at day 10 after immunization. We measured 
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the proportion of GC B cells, PCs, and Tfh cells from draining lymph nodes (dLN) (Figure 
25). Unfortunately, the results from the transfer experiments were inconsistent. GC B cells 
and PCs were decreased in the first experiment (Figure 25A), but not in the second 
experiment (Figure 25B). As was the case with the GC B cell frequencies, contradictory 
results were observed in the antibody measurement of the two independent experiments 
(Figure 26). In the first experiment, levels of NP-specific general affinity IgM and IgG were 
decreased in CXCR5-transduced Treg cell recipients (Figure 26A). In the second experiment, 
levels of NP-specific both high and general affinity IgM were decreased while those of IgG 
were increased in CXCR5-transduced Treg cell recipients (Figure 26B).   
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Figure 24. A schematic diagram of adoptive co-transfer experiment using immunized 
Tfh and RV-transduced Treg cells. Congenic B6SJL mice were immunized with NP-KLH 
on Day 0. On Day 2, Treg cells were isolated from RIF mice and infected with Control or 
CXCR5-RV, followed by cell expansion. On Day 7, FACS-sorted 50,000 of Tfh (PD-
1
+
CXCR5
+
CD4
+
) cells from NP-KLH immunized B6SJL mice and 25,000 of GFP
+
RFP
+
 
Treg cells were cotransferred into TCRβ KO mice followed by immunization of recipient 
mice with NP-KLH. 10 days later, sera were collected and draining lymph nodes were 
obtained for further studies. 
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Figure 25. GC responses in mice co-transferred with Tfh and RV-transduced Treg cells 
are inconsistent. Two independent cotransfer experiments (A and B) of GC responses (GC 
B cells, PCs, and Tfh cells) from dLN of TCRβ KO recipients. (A) The frequencies of GC B 
cells and PCs were statistically decreased in CXCR5-transduced Treg cells recipients. (B) No 
significant changes in GC B cell responses were detected. The frequency of Tfh cells slightly 
increased in CXCR5-transduced Treg cells recipients in both experiments (A and B). Data 
are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 26. NP-specific immunoglobulin levels in mice co-transferred with Tfh and RV-
transduced Treg are inconsistent. Two independent cotransfer experiments (A and B) of 
NP-specific immunoglobulin levels (IgM and IgG, NP4 for high affinity and NP32 for 
general affinity) in the sera from TCRβ KO recipients. (A) Both IgM and IgG levels were 
decreased in CXCR5-transduced Treg cell recipients. No statistical difference between the 
groups. (B) IgM levels were decreased in CXCR5-transduced Treg recipients while IgG 
levels were increased in CXCR5-transduced Treg recipients. Data are represented as mean ± 
SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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We reasoned that the small numbers of transferred cells used in the above-mentioned 
experiment could be the cause of the inconsistent results. Therefore, we modified the 
experimental design by using another transfer model from a recent study [110]. Instead of 
Tfh cells from NP-KLH immunized mice, we transferred naïve CD4
+
 T cells and also 
increased the number of transferred to 500,000 cells (Figure 27). 5 days after ex vivo 
expansion of  RV-transduced Treg cells, FACS sorted naïve CD4
+
 T cells (CD4
+
CD25
-
CD44
-
CD62L
+
) from congenic B6SJL mice and GFP
+
RFP
+
 Treg cells were adoptively 
transferred into TCRβ KO mice.  
First, we compared RV-transduced Treg cell stability after cell transfer. As shown in 
Figure 28, there was no difference in the frequency of transferred Treg cells between 
Control-transduced Treg cell recipients and CXCR5-transduced Treg cell recipients. As we 
increased the number of transferred cells (bottom panels), we observed increased frequencies 
of live donor GFP
+
RFP
+
 Treg cells in the dLNs. Therefore, we next examined the role of 
CXCR5-transduced Treg cells in GC reactions in this experimental setting. The frequencies 
of GC B cells and Tfh cells were slightly decreased in CXCR5-transduced Treg cell 
recipients group, but the differences were not statistically significant (Figure 29A and 29C). 
The frequency of PCs was comparable between Control-transduced Treg recipients and 
CXCR5-transduced Treg cell recipients (Figure 29B). Levels of NP-specific both high and 
general affinity IgM were increased in sera from CXCR5-transduced Treg cell transferred 
group (Figure 30A). However, NP-specific high and general affinity IgG levels were 
comparable between Control-transduced Treg recipients and CXCR5-transduced Treg cell 
recipients (Figure 30B). Our results indicated that CXCR5-transduced Treg cells in these 
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experiments did not show stronger suppressive function of antigen-specific GC reactions in 
vivo.   
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Figure 27. A schematic diagram of modified adoptive co-transfer experiment using 
naïve CD4
+
 T cells and RV-transduced Treg cells. On Day 0, Treg cells were isolated from 
RIF mice and infected with Control or CXCR-RV, followed by cell expansion. On Day 5, 
5,000,000 of FACS-sorted naïve CD4
+
 T  (CD4
+
CD25
-
CD44
-
CD62L
+
) cells from B6SJL 
mice and 500,000 of GFP
+
RFP
+
 Treg cells were transferred into TCRβ KO mice followed by 
immunization of recipient mice with NP-KLH. On Day 16, sera were collected and draining 
lymph nodes were obtained for further studies. 
 
 
  
７６ 
 
Figure 28. Comparison of transferred RV-transduced Treg cells in different 
experimental designs. The frequencies of RV-transduced Treg cells from Figure 23  
(upper panel) and Figure 26 (bottom panel) in the draining lymph nodes of recipients.  
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Figure 29. GC responses in mice co-transferred with naïve CD4
+
 T cell and RV-
transduced Treg cells. GC responses (GC B cell, PC, and Tfh cells) from dLN of TCRβ KO 
recipients. The proportion of GC B cells (A) and Tfh cells (C) were slightly decreased in 
CXCR5-transduced Treg cell transferred group, but the data were not statistically significant. 
The frequency of PCs (B) was comparable between the groups. Data are represented as mean 
± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 30. NP-specific immunoglobulin levels in mice co-transferred with naïve CD4
+
 T 
cells and RV-transduced Treg cells. NP-specific immunoglobulin levels (IgM and IgG, 
NP4 for high affinity and NP32 for general affinity) in the sera from TCRβ KO recipients. (A) 
NP-specific both high and general affinity IgM levels were higher in CXCR5-transduced 
Treg cell transferred group. (B) NP-specific both high and general affinity IgG levels were 
comparable between the groups. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001. 
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3. Discussion 
 Abnormal generation and function of Tfh cells contribute to the pathogenesis of 
autoimmune diseases. Therefore, regulating aberrant Tfh cell activity is a key mechanism to 
relieving autoantibody-mediated autoimmune diseases. For the treatment of autoantibody-
mediated autoimmune lupus, many non-biological reagents are currently being used. 
However, many side effects and non-specific immunosuppression have been reported in 
clinical studies. The use of Tfh specific regulatory Treg cell subset, Tfr cell, has been 
proposed an alternative autoimmune disease immunotherapy. Owing to the rare number of 
Tfr cells in normal conditions, Tfr cells are limited in possible therapeutic applications. 
Numerous studies demonstrate that CXCR5 is the key chemokine receptor for the migration 
of immune cells into GC area [39-41]. In addition, direct regulation of auto-reactive B cells 
by Treg cells has been reported [104-106]. Therefore, to examine an alternative to the Tfr cell 
limitations, we generated CXCR5 overexpressing Treg cells by retroviral transduction and 
examined their suppressive roles in GC responses.  
Our results demonstrated that overexpression of CXCR5 did not affect Treg gene 
expression profile (Figure 21). Except Cxcr5, other Tfh or Treg cell representative genes 
such as Foxp3, Bcl6, Prdm1, Pd1, Icos, and Ctla4 expression levels were not altered. 
Moreover, these CXCR5-transduced Treg cells did not lose their suppressive activity in vitro 
(Figure 22). Even after retroviral transduction, CXCR5-transduced Treg cells had similar 
suppressive properties as Control-transduced Treg cells. CXCL13 dependent chemotactic 
migration is mediated by CXCR5 expression and signaling. This feature is also shown in 
CXCR5-transduced Treg cells (Figure 23). Using in vitro transwell system, we demonstrated 
８０ 
 
that CXCR5-transduced Treg cells migrated in response to CXCL13 in a dose-dependent 
manner. The in vitro suppressive and migratory functions of CXCR5-transduced Treg cells 
appeared therefore promising as a possible cellular therapeutic for autoimmune diseases. To 
test the immunosuppressive effects of these transduced Treg cells, we used two different in 
vivo adoptive transfer experiments in T cell-deficient mice.  
Unfortunately, the results from these experiments were not consistent, suggesting that 
our experimental designs will need to be further refined. For example, the initial Tfh cell co-
transfer experiments were not reproducible. Since the number of transferred cells was 
relatively small (50,000 of Tfh cells and 25,000 of RV-transduced Treg cells), we suspected 
that was the main cause of inconsistent results. Next we modified the experiment and tested 
the role of CXCR5-transduced Treg cells. We showed the decrease of GC B cell and Tfh 
cells in CXCR5-transduced Treg cell recipients, but again we did not observe meaningful 
results. When we checked the transferred cell stability, we could clearly detect Foxp3 
expression in RV-transduced Treg cells (Figure 28). Accumulating studies strongly support 
that the expression of Foxp3 gene is correlated with their suppressive capacity in T cells [17]. 
We did demonstrate a stable Foxp3
+
 population in the recipients, so they likely are providing 
a suppressive role. However, to clearly demonstrate the suppressive function of these 
CXCR5-transduced Treg cells, we will need to find the optimal condition of transfer or 
perhaps employ more suitable animal model.  
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General discussion and future directions 
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1. General discussion 
1.1. Tfh cells in antibody-mediated autoimmune diseases 
 Autoimmune diseases contain more than 100 different types of disorders 
characterized with various pathogenesis [1]. However, many of their pathogenic mechanisms 
are not clearly defined. In the United States alone, more than 50 million Americans suffer 
from autoimmune diseases with an estimated annual cost of autoimmune related diseases is 
more than $100 billion [1]. Multiple genetic and environmental factors are known to trigger 
the breakdown of immune tolerance to self-antigens and lead to autoimmune diseases [115]. 
The generation of auto-reactive antibodies against self-antigens including nuclear 
components, organ-specific antigens, and soluble factors, is a hallmark of autoantibody-
mediated autoimmune diseases [115]. As Tfh cells principal role is to support GC B cell 
responses, accumulated studies in both mice and humans strongly support that abnormal 
generation and/or activation of Tfh cells are associated with the pathogenesis of 
autoantibody-mediated autoimmune diseases. Understanding the role of Tfh cells is 
important for developing treatment of antibody-mediated autoimmune diseases. In this regard, 
we aimed to study the role of Tfh cells and Tfr cells in animal model of autoimmune lupus in 
the present study. 
1.2. BXD2 mice as an animal model of antibody-mediated autoimmune lupus 
 To appropriately study autoantibody-mediated autoimmune diseases, we need a 
suitable and representative animal disease models. There are many mouse autoimmune 
disease models (Table 4). Among them, the BXD2 strain is the most optimal mouse 
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autoimmune disease model. First of all, BXD2 mice spontaneously develop autoimmune 
lupus, arthritis and glomerulonephritis which are common symptoms in patients with 
autoimmune diseases [118]. Second, unlike Fas-deficient MRL/lpr mice, BXD2 mice do not 
have significant gene deficiency while having several autoimmune loci, related to 
autoimmune phenotypes [118]. Interestingly, IL-17 drives autoantibody-mediated 
autoimmune responses by promoting spontaneous GC formation in the BXD2 mice [117]. 
Therefore, we employed BXD2 mice as an autoimmune disease model for experimental T 
cell-mediated therapy.  
1.3. Tfh cell, rather than Th17 cell, mediates auto-reactive GC responses in BXD2 mice  
We first inspected the general phenotypes of BXD2 mice. As described in previous 
studies, BXD2 mice developed auto-reactive B cell responses in comparison to age-matched 
wild-type mice, including increased number of GCs, proportion and number of GC B cells, 
autoantibodies titers in sera, and proportion and number of Tfh cells [142]. In contrast to 
another study, the percentage of IL-17 positive CD4
+
 T cells, levels of IL-17 in the 
circulation, and Th17 cell related genes expression were not increased in our investigations 
of BXD2 mice. Based on these observations, we re-investigated the mechanism of auto-
reactive GC reaction in the BXD2 mice. Our results showed that Tfh cells, rather than Th17 
cells had positive correlations with the GC responses including the proportion of GC B cells, 
and autoantibody levels. Moreover, we clearly proved that IL-21, not IL-17 was essential for 
initiating the production of IgG from naïve B cells. Including our study, many other studies 
suggest that IL-21 has a critical role in inducing terminal B cell differentiation and a potential 
role for further development of autoimmune diseases [141]. Our results also bolstered the 
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role of Tfh cells in the development autoimmune lupus. IL-21 is induced by IL-6, which is 
also critical for Th17 cell differentiation, and Th17 cells also express IL-21 [150]. Therefore, 
targeting IL-21 might be effective for suppressing Tfh as well as Th17 responses. There are 
several on-going clinical trials using blocking IL-21 for RA and SLE [141]. Therefore, 
regulation of IL-21 and its signaling pathway would be effective therapeutics not only for the 
autoantibody-mediated autoimmune diseases, but also other autoimmune diseases, in which 
Tfh and Th17 cells are simultaneously involved in disease onset and progression, such as RA.  
Increased levels of IL-17 in the circulation in patients with SLE support the role of 
IL-17 in auto-reactive B cell responses [153]. However, other studies have argued that there 
is no strong correlation between levels of IL-17 and auto-reactive disease, even IL-17 levels 
were increased in SLE patients [154-156]. Our studies with BXD2 mice study demonstrated 
no correlation between Th17 cell/IL-17 and the generation of autoimmune B cell responses. 
Therefore, the pathologic role of IL-17/Th17 cells in auto-reactive GC responses is remains 
somewhat controversial and warrants further investigation. 
The differences in the results of our study and that of the Mountz laboratory regarding 
examining of Th17 cells in autoimmune B cell responses in BXD2 mice is presently not clear. 
One potential explanation is that differences in diet or gut microbiota may result in different 
levels of Th17 responses in the two studies. All mice in chapter 2 were purchased from 
Jackson Laboratory, known to be SFB free [143], and maintained in a barrier facility. 
However, the proportion of Th17 cells in the mesenteric lymph node and Peyer’s patches of 
BXD2 mice was similar to that of control mice even after 4 weeks of co-housing (Figure 9). 
Therefore, the difference of Th17 cell immunity between previous studies and our study is 
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not likely because BXD2 mice retained less Th17-associated gut microbiota than control 
mice in our study. Instead, we observed an increase of IFN-γ-producing Th1 cells, not IL-17-
producing Th17 cells in BXD2 mice (Figure 7). Th1 and Th17 cells reciprocally regulate 
each other and IFN-γ is also associated with autoimmune diseases [157]. Sanroque mice have 
excessive IFN-γ and sustain lupus-associated pathology [126]. These results may explain 
why BXD2 mice have less Th17 cell immunity and IFN-γ mediated auto-reactive 
autoantibodies generation in BXD2 mice in our experiments. Further study will be necessary 
to determine the role of Th1/IFN-γ in auto-reactive GC responses in BXD2 mice. 
A previous study demonstrated that IL-21 suppresses Tfr cell development in BXD2 
mice [119]. Similar to this previous report, our present investigation showed that the 
frequency of Tfr cells was decreased while that of Tfh cells was increased in BXD2 mice 
(Figure 10 and 12). Moreover, the ratio of GC B cell per Tfr cell and Tfh cell per Tfr cell 
were increased in BXD2 mice. This imbalance between Tfh and Tfr cells likely contributes 
to the observed autoimmune lupus in BXD2 mice, indicating that this aberrant immune 
homeostasis leads to the development of autoimmune diseases. Our findings indicate that 
reconstituting balance between Tfh cells and Tfr cells, either decreasing Tfh cells or 
increasing Tfr cells, might be the key to developing new treatments for autoantibody-
mediated autoimmune diseases.  
1.4. Use of Engineered Tfr-like cells is as a novel cellular therapeutics for the treatment 
of antibody-mediated autoimmune diseases 
 As described in Table 2, immunosuppressive chemical agents are generally being 
used to relieve the autoimmune inflammatory symptoms in patients with SLE. However, 
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many of these agents report side effects or only have partial specificity [2]. For example, due 
to their systemic immune suppressive function, non-biological reagents also downregulate 
normal, unnecessary immune functions. 
On the other hand, Tfr cells control GC reactions by suppressing either Tfh cell or GC 
B cells and prevent the emergence of auto-reactive B cells [24, 25, 116]. Also, transfer of Tfr 
cells greatly reduced the auto-reactive B cell responses in BXD2 mice [116, 119]. These 
results indicated that Tfr cells have GC response-specific suppressive function and efficiently 
regulate auto-reactive B cell responses and autoantibody productions. Therefore, Tfr cells are 
a novel candidate for the treatment of autoantibody-mediated autoimmune diseases. However, 
this approach has a significant hurdle to overcome in that it will be difficult to obtain enough 
Tfr cells for effective therapy.  
To overcome this drawback, we hypothesized that enforcing CXCR5 expression on 
the more abundant Foxp3
+
 Treg cells will facilitate robust migration of Treg cells to the GC 
area, thereby suppressing auto-reactive reactions in the GCs. Several studies have 
demonstrated that Treg cells regulate GC responses [116] and expression of CXCR5 enables 
cells to migrate into B cell follicles [39-41, 60]. We generated CXCR5-transduced Treg cells 
and expanded these cells ex vivo to acquire sufficient number of cells for investigation.  
Overexpression of CXCR5 specifically on Treg cell did not affect the expression of 
other genes related to Tfh cells or Treg cells (Figure 21). Likewise, retroviral transduction of 
CXCR5 on Treg cells did not impair the quality of suppression in vitro (Figure 22). Most 
importantly, the CXCR5 expression on Treg cells empowered these cells to migrate in a 
CXCL13 dependent manner during an in vitro transwell assay (Figure 23). A recent study 
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with conventional CD4
+
 T cells also indicated that expression of CXCR5 enhances cell 
migration toward GC area [60]. Collectively, these in vitro experimental results strongly 
support the possibility of this cell as a drug candidate for diseases dependent on Tfh cell 
activity. We next tested the in vivo the possible immunomodulatory function of CXCR5-
transduced Treg cells in adoptive transfer experiments. We designed two different adoptive 
transfer experiments based on several references [107, 110, 152]. To exclude the role of Tfh 
or Tfr cells from the host mice, we used TCRβ KO mice which have no endogenous T cells 
in all adoptive transfer experiments.  
The co-transfer experiments with NP-KLH immunized Tfh cells and RV-transduced 
Treg cells yielded data that was highly variable and inconsistent (Figure 24). Since we 
transferred only 50,000 of Tfh and 25,000 of RV-transduced Treg cells into the recipients, 
we assumed that increasing number of transferred cells would provide an experimental 
system that can define the function of eTfr cells in vivo. We thus transferred naïve CD4
+
 T 
cells, instead of immunized Tfh cells and increased the numbers of transferred cells by 
transferring 5 million of naïve CD4
+
 T cells and 500,000 of RV-transduced Treg cells into 
TCRβ KO mice. Even in this setting, we still did not observe clear differences between GC 
responses of Control and CXCR5-transduce Treg cell recipients. We successfully 
demonstrated the migration of CXCR5-transduced Treg cells in response to CXCL13 in vitro, 
and a recent in vivo study with conventional CD4
+
 T cells [60]; however, it is unclear 
whether CXCR5-transduced Treg cells efficiently migrated into B cell zone at this stage. 
Therefore, it is necessary to determine whether CXCR5-transduced Treg cells have in vivo 
migration capacity to CXCL13 gradient into B cell zone by using immunohistological 
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examination. However, we did detect reliable numbers of GFP
+
RFP
+
 Treg cells in the 
recipients (Figure 28, bottom). Since the expression of Foxp3 in T cells is critical for their 
suppressor activity [17], transferred Treg cells might have a suppressive function. Moreover, 
ectopic expression of Foxp3 in conventional T cells induced the conversion of conventional 
T cells into Treg-like cells and had suppressive function [158-160].Therefore, we may 
generate Tfr-like cells from Tfh cells by overexpressing Foxp3. This method is relatively 
simpler and cost-effective than generating eTfr cells from CXCR5-transduced Treg cells. 
Nevertheless, Foxp3 is a transcription factor, and this transcription factor will induce many 
changes in other genes expressions while transduction of CXCR5 did not affect other genes 
profile. Therefore, we believe that generation of eTfr cells from CXCR5-transduced Treg is 
more reliable system than from Foxp3-transduced Tfh cells. Thus, improving the quality and 
quantity of eTfr cells are also critical issue in our future study for the development of Tfr 
cell-based immunotherapy.  
Numerous studies have performed adoptive transfer experiments of Treg including 
nTreg or peripheral Treg (pTreg), and these cells are about sufficient to suppress the auto-
reactive B cell responses [4, 18, 161]. As we first hypothesized, if this transferred cells 
successfully migrated into GC area, perhaps, if with further optimization of this transfer 
condition, we will observe better and more consistent suppression in the GC responses. 
As described above, we designed in vivo experiments based on the publications which 
used T cell or immune cell-deficient mice [107, 110, 152]. Although using TCRβ KO mouse 
has some benefits in our experimental setting, this strain provides incomplete T cell 
immunity. Therefore, this imperfect condition of host mice may cause the conversion of 
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transferred eTfr cells, either non-Treg cell (loss of Foxp3 expression) or other T helper 
subsets. This might be another reason why we could not gain consistent results in both 
experimental settings. Therefore, use of alternative mouse model for the in vivo experiment 
might be necessary to address functional aspects of eTfr cell in vivo. There are two different 
conditional depletion of Foxp3
+
 Treg cell mice [162, 163]. Utilizing this mice, we can focus 
on the function of transferred cells while minimalizing the inadequate T cell immune 
responses.  
1.5. Conclusion 
Overall, our current study demonstrated a crucial role for Tfh cells in auto-reactive B 
cell responses in BXD2 mice and from these findings proposed a possible alternative 
immune cell-based therapeutic approach for autoimmune disease by using CXCR5-
transduced Treg cells. In vitro, the CXCR5-transduced Treg cells behaved as hoped with 
both chemoattractant and immunosuppressive properties. We still feel that with continued 
effort in enhancing the transfer procedures that the therapeutic use of CXCR5-transduced 
Treg cells will be validated in vivo with the BXD2 mice.  
 
2. Future Directions 
2.1. Investigate the role of Th1 cells/IFN-γ in the development of autoimmune diseases 
Our present study successfully showed the roles of Tfh cells and IL-21 in the BXD2 
mouse model of autoimmunity. An increase of Th1 cells, instead of Th17 cells was also 
observed. The role of IFN-γ in the development of autoimmune disease has also been 
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reported [126, 157]. Therefore, IFN-γ, secreted by Th1 cells may have a role in autoimmune 
disease onset. However, we could not explain the mechanism behind the increase of Th1 
cells in the BXD2 mice. Therefore, we propose in future investigations to determine the role 
of Th1 cell responses in the generation of auto-reactive GC responses in BXD2 mice. We 
will investigate whether excessive IFN-γ signaling affects in auto-reactive GC responses in 
BXD2 mice. By blocking IFN-γ signaling, we will also address whether this blocking will 
relieve the autoimmune phenotypes in BXD2 mice.  
2.2. The ways to improve the quantity and quality of eTfr cells 
Multiple studies strongly supported the idea that the application of Treg cells as an 
immunosuppressor in many autoimmune diseases and accordingly we successfully 
demonstrated the function of eTfr cells in vitro. Nevertheless, we did not show the function 
of eTfr cells in vivo. Since our current experimental design is not optimized, we will first 
address this problem. Future studies will need to test different conditions of adoptive transfer; 
for example, increase the ratio of RV-transduced Treg cells (naïve T:RV-Treg = 10:1 to 5:1 
or higher) in adoptive transfer experiments.  
In adoptive transfer experiments, the number and the quality of transferred cells are 
critical for the outcome, and these issues will likely need to be addressed in future studies. A 
recent paper demonstrated that adoptive transfer of Tfr cells inhibited Tfh cells and 
suppressed GC development and autoantibody production in an animal autoimmune disease 
model [119]. To get a sufficient number of Tfr cells, they isolated Tfr cells from IL-21-
deficient BXD2 mice, which increased the frequency of Tfr cells. However, there still 
remains the problem of obtaining enough number of Tfr cells for human therapeutics. 
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Expression of Foxp3 in T cells is critical for their suppressor activity [17]. Additionally, 
maintaining expression of Foxp3 is essential for the continued suppressive quality of Treg 
cells. In addition, IL-2 signaling is also involved in Treg cell expansion and homeostasis 
[164]. Thus, there are many ways to manipulate the number and quality of Treg cells for 
future studies (Figure 31).  
 
Figure 31. General strategies for the manipulation of Treg cells in autoimmunity.  
 
Adapted with permission from von Boehmer H and Daniel C, Therapeutic opportunities for 
manipulating T(Reg) cells in autoimmunity and cancer. Nature reviews. Drug discovery, 
2013. 12(1): p. 51-63. 
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Either ex vivo or in vivo expansion of eTfr cells are shown potential ways to increase 
the yield of eTfr cells. When we expanded the eTfr cells ex vivo, we used a relatively low-
dose mouse IL-2 (50 U/ml). However, other studies demonstrated that a high dose of IL-2 
can promote the proliferation of Treg cells ex vivo [18, 165-167]. Moreover, the 
administration of IL-2 together with an IL-2-specific monoclonal antibody (JES6-1) leads to 
rapid expansion of Foxp3
+
 Treg cells in vivo [164, 168, 169]. Since IL-2 inhibits Th17 
differentiation [170], this may prevent transferred eTfr cells from conversion to other T 
helper subsets. 
Increase the eTfr cell survival and stability may be another way to improve either 
quantity or quality of eTfr cells. Treatment of PI3K-AKT-mTOR inhibitors or DNA 
methyltransferase 1 inhibitors such as 5-aza-2-deoxycytidine (5-Aza) enhance the Treg cell 
survival and stability [18, 164, 171, 172]. Alternatively, by administration of fingolimod 
(FTY720) or by targeting miRNAs such as miR-155 and miR-146a, the suppressive function 
of Treg cells can be augmented [30, 164, 173-176].   
Several studies demonstrated that antigen-specific Treg cells are more efficient in 
inhibiting pathogenic immune responses compared to polyclonal Treg cells in many disease 
model systems [177]. Therefore, induction of strong agonistic TCR signals, such as self-
antigen or immunogen, under subimmunogenic conditions are required to generate stable 
Treg cells [164]. Since subimmunogenic conditions may not activate the pathway involving 
PI3K-AKT-mTOR, this enables cells to induce stable Foxp3 expression [164]. Instead, 
generating genetically targeted Treg cells using antigen-specific TCR transgenic Treg cells or 
chimeric antigen receptor (CAR) may enhance the suppressive activity of Treg cells. CAR
+
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cells can generate the desired numbers of cells with targeted specificity without the need co-
receptor engagement or HLA restriction. 
Alternatively, pTreg cells can be utilized, instead of nTreg cells, for generating eTfr 
cells. Unlike thymus-derived nTreg cells, pTreg cells can be differentiated from conventional 
CD4
+
 T cells under variable stimulatory conditions in the periphery, and have a distinct 
suppressive mechanism compared to the nTreg cells [178]. In addition, pTreg cells can be 
easily differentiated from naïve CD4
+
 T cells by IL-2 and TGF-β stimulation. Since pTreg 
cells are being used to control autoimmunity in various animal models of autoantibody-
mediated autoimmune diseases [179], albeit Tfr cells are originated from nTreg cells [24, 25], 
we may utilize pTreg cells for generating eTfr cells. Moreover, since a greater number of 
naïve CD4
+
 T cells is available than nTreg cells, generating a large number of eTfr cells from 
pTreg may be easier than from nTreg cells. 
2.3. Regulation of IL-21/IL-21 signals will provide the synergistic effect on eTfr cell-
based immunotherapy  
IL-21, a major cytokine of Tfh cells, has a direct role in GC responses and is 
associated with autoimmune disease development [141]. IL-21 has a suppressive role in Tfr 
cell differentiation and function [119]. Moreover, many on-going autoimmune disease 
clinical trials are based on blocking IL-21 and its signal pathway [141]. Therefore, if eTfr 
cell based immunotherapy were perfected, combining two different treatments, eTfr cell 
transfer and blocking IL-21/IL-21 signaling should have a synergistic effect on alleviating 
autoantibody-mediated autoimmune diseases.   
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This chapter is based on and reproduced from the following journal article. As per PLoS 
policy, no permission is required to reprint: Kim YU, Lim H, Jung HE, Wetsel RA, and 
Chung Y (2015) Regulation of autoimmune germinal center reactions in lupus-prone BXD2 
mice by follicular helper T cells. PLoS ONE 10(3): e0120294. 
doi:10.137/journal.pone.012294 
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1. Mice 
 C57BL/6, Foxp3-IRES-mRFP (FIR), B6SJL (CD45.1), Tcrb
-/- (TCRβ KO), and 
BXD2 mice were purchased from Jackson Laboratory. All mice were maintained in the 
specific pathogen-free facilities at the vivarium of the Institute of Molecular Medicine, the 
University of Texas Health Science Center at Houston. All animal experiments were 
performed using protocols approved by Institutional Animal Care and Use Committee of the 
University of Texas at Houston.  
2. Cell isolation and culture 
 Total B cells and CD4
+
 T cells were obtained using anti-CD45R and anti-CD4 MACS 
columns (Miltenyi Biotech). B220
+
GL7
-
IgD
+
 Naïve B cells, and CD4
+
CD25
-
CD44
-
CD62L
+
 
naïve T cells from mouse spleen and peripheral lymph nodes were sorted by the FACSAria II 
(BD Biosciences). Treg cells from FIR mice were obtained using Treg isolation kits and 
stimulated Treg cells used Treg expansion kits (all from Miltenyi Biotech), according to the 
manufacturer’s protocols with a small modification (50 U/ml of mIL-2, instead of 1000 
U/ml).  
Primary T and B cells were cultured in RPMI 1640 medium (Lonza) supplemented 
with 10% FBS, 55 μM 2-mercaptoethanol, 2 mM L-glutamine, 100 units penicillin-
streptomycin (all from Gibco), and 10 μg/ml Gentamicin (Sigma-Aldrich). 293T cells were 
cultured in DMEM medium (Lonza) supplemented with 10% FBS 4.5g/l glucose, 2mM L-
glutamine, and 100 units penicillin-streptomycin.  
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For in vitro Th17 cell differentiation, sorted CD4
+
CD25
-
CD44
-
CD62L
+
 naïve T cells 
were stimulated for 5 days with plate-bound of anti-CD3(1 μg/ml) and anti-CD28 (1 μg/ml), 
in the presence of 2 ng/ml recombinant human TGF-β, 10 ng/ml recombinant mouse IL-6 (all 
purchased from Peprotech), 40 ng/ml recombinant mouse IL-23 (R&D systems), 10 μg/ml 
anti-mouse IFN-γ (clone XMG 1.2, BioXcell) and 10 μg/ml anti-mouse IL-4 (clone 11B11, 
BioXcell). 
3. CXCR5 cloning and retroviral transduction  
 Mouse CXCR5 cDNA PCR fragment was prepared using iProof High-Fidelity DNA 
polymerase (Biorad), with CXCR5 cloning primer sets (Forward 5’-
ATCGAGATCTATGAACTACCCACTAACCCTGGAC-3’ and Reverse 5’-
ATCGCTCGAGCTAGAAGGTGGTGAGGGAAGTAGC-3’). After Bgl II and Xho I (all 
from New England Biolabs) enzyme digestion, the mCXCR5 fragment was ligated into the 
unique BglII and XhoI site of RV-GFP vector using T4 ligase (Invitrogen). 10 μg of pCL-Eco 
packaging vector with 10 ug of control or CXCR5-RV-GFP vector were co-transfected into 
the 293T cells using calcium phosphate/chloroquine (100 μM, Sigma) method. 24 hours after 
Treg cells stimulation and retroviral transfection, cells were infected with retroviruses 
CXCR5-RV-GFP or control empty vector with 8 ug/ml of polybrene (Sigma). 4 days after 
the infection, GFP and RFP double positive cells were FACS sorted for further approaches. 
4. In vitro Treg suppression assay 
 Cell proliferation dye eFluor670 (eBioscience, 5 μM) labeled responder CD4+ T cells 
(Tresp, 1 × 10
5
) from congenic B6SJL mice were co-cultured with indicated ratio of 
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GFP
+
RFP
+
 FACS sorted retroviral transduced Treg cells in a U-bottom 96-well plate in the 
presence of 0.5 μg/ml of anti-CD3 and irradiated (3000 rad) T cell-depleted splenocytes (1 × 
10
5
) for 3 days. Proliferation of the Tresp cells was measured by eFluor670 dilution among the 
CD4
+
CD45.1
+
 population by flow cytometry.   
5. In vitro cell migration assay 
 3 × 10
5
 GFP
+
RFP
+
 sorted retroviral transduced Treg cells were rested at 37 °C for 2 
hours in complete RPMI media before a migration assay. Cells were placed in the upper 
chamber (Corning, Polycarbonate, 6.5mm diameter, 5 μm pore size) containing 100 μl of 
complete RPMI media with the lower chamber containing 600 μl complete RPMI media with 
various concentrations of CXCL13 (PeproTech). After 4 hours of incubation, cells from the 
lower well were collected and examined with a FACS Calibur for 1 minute at 60 μl/min of 
flow rate in triplicates. Migration index was calculated as follows: ((number of migrated 
cells/number of input cells)*100) 
6. Adoptive transfer studies and keyhole limpet hemocyanin immunization  
 B6SJL mice were subcutaneously (s.c.) immunized at the tail base with 100 μl of 4-
Hydroxy-3-nitrophenylacetyl hapten-conjugated keyhole limpet hemocyanin (NP-KLH, 0.5 
mg/ml, Biosearch Technologies) emulsified in CFA (Sigma). Seven to ten days later, 
CD4
+
PD-1
+
CXCR5
+ 
Tfh cell population from draining lymph nodes of immunized mice 
were isolated by flow cytometry. 5 × 10
4
 of Tfh cells from B6SJL and 2.5 × 10
4
 of control or 
CXCR5-transduced Treg cells were adoptively cotransferred into Tcrb-/- mice. Or 3~5 × 10
6
 
of naïve CD4
+
 T cells from B6SJL mice were isolated by flow cytometry and 5 × 10
5
 of 
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control or CXCR5-transduced Treg cells were adoptively cotransferred into Tcrb-/- mice. 
The next day, the recipient mice were s.c. immunized with NP-KLH in CFA. Seven to ten 
days later, lymphoid cells from draining lymph nodes of recipient mice were collected and 
analyzed for further studies.  
7. Flow cytometry 
For cell phenotype analysis, lymphoid cells isolated from mouse spleens, peripheral 
lymph nodes, and Peyer’s patches were obtained and stained with PerCp-Cy5.5-conjugated 
anti-CD4 (clone GK1.5, BioLegend), APC-conjugated anti-CD45R/B220 (clone RA3-6B2, 
BioLegend), Pacific blue-conjugated anti-CD45.1 (clone A20, BioLegend) or CD45.2 (clone 
104, BioLegend), PE-conjugated anti-CD138 (clone 281-2, BioLegend), Alexa488 anti-GL7 
(clone GL7, BD Pharmingen, San Jose, CA), PE-conjugated anti-CD95 (Fas, clone 15A7, 
eBioscience), FITC-conjugated anti-CD279 (PD-1, clone J43, eBioscience), Brilliant-Violet-
421-conjugated anti-CD279 (clone 29F.1A12, BioLegend), PE-conjugated anti-CD184 
(CXCR4, clone L276F12, BioLegend), Biotin-conjugated anti-CD185 (CXCR5, clone 
L138D7, BioLegend), PE or APC-conjugated Streptavidin (BioLegend), Alexa647-
conjugated CD196 (CCR6, clone 140706, BD Pharmingen). 
For intracellular cytokine staining, lymphoid cells isolated from mouse spleens, 
peripheral lymph nodes, and Peyer’s patches were stimulated with PMA (100 ng/ml, Sigma-
Aldrich) and ionomycin (1 μM, Sigma-Aldrich) in the presence of Brefeldin A and Monensin 
(all from eBioscience) for 4 hours, followed by staining with PerCp-Cy5.5-conjugated anti-
CD4. The cells were then resuspended in permeabilization buffer (eBioscience) for 30 min at 
4°C, followed by staining with PE-conjugated anti-IL-17A (clone TC11-18H10.1, 
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BioLegend), Alexa488-conjugated anti-IFN-γ (clone XMG1.2, eBioscience). For IL-21 
staining, after permeabilization, cells were stained with Alexa488-conjugated anti-IL-17A 
(clone TC11-18H10.1, BioLegend), recombinant mouse IL-21R-Fc Chimera (R&D Systems), 
followed by APC or PE-conjugated human Fc IgG (R&D Systems).   
For Foxp3
+
 cell detection, after surface staining, cells were incubated in Foxp3 
staining buffer (eBioscience) for 30 min, followed by Alexa488-conjugated anti-Foxp3 
(clone 150D/E4, eBioscienece). The stained cells were analyzed by FACSAria II flow 
cytometer (BD Bioscience, San Jose, CA), and the data were analyzed using FlowJo software 
(TreeStar, Ashland, OR). 
8. Immunohistochemical Analysis 
Mouse spleens or draining lymph nodes were fixed in 4% paraformaldehyde 
embedded in Tissue-Tek O.C.T compound (Sakura Finetek, Torrance, CA), and cut into 6 
μm sections. The slides were incubated for 30 min with Image-iT FX Signal Enhancer (Life 
Technologies). After washing, slides were incubated with BlockAid Blocking Solution (Life 
Technologies) for 30 min, and then stained with Biotinylated Peanut Agglutinin (PNA, 
Vector Laboratories, Burlingame, CA), and hamster anti-mouse CD3e (clone 145-2C11, 
BioXcell). The slides were further incubated with Pacific Blue-conjugated anti-IgD (clone, 
11-26c.2a, BioLegend), DyLight649-conjugated anti-Hamster IgG (clone Poly4055, 
BioLegend), and DyLight594-conjugated Streptavidin (Pierce Biotechnology). The slides 
were mounted with Fluoromount-G (SouthernBiotech). Images were acquired with a Nikon 
TE2000E fluorescence microscope equipped with a Photometrics Coolsnap HQ2 camera. 
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9. In vitro co-culture assay 
B220
+
GL7
-
IgD
+
 Naïve B cells, CD4
+
CXCR5
+
 and CD4
+
CCR6
+
 T cells from BXD2 
mouse spleen were sorted by the FACSAria II (BD Biosciences). For in vitro antibody 
production assay, sorted 1 × 10
5
 Naïve B cells and diverse ratio of CXCR5
+
 or CCR6
+
 CD4 
T cells or in vitro differentiated Th17 cells were co-cultured in the presence of 2 μg/ml 
soluble anti-CD3e (clone 145-2C11, BioXcell) and anti-IgM (AffiniPure F(ab’)2 Fragment 
Goat anti-IgM, μ chain specific, Jackson ImmunoResearch) for 7 days.  
For cytokine blockade, 10 μg/ml of recombinant human Fc-G1 (Human Fc-G1, 
BioXCell), anti-IL-17A (clone 50104, R&D Systems) or recombinant mouse IL-21R-Fc 
Chimera (R&D Systems) was added into the B and T cell co-culture every other day. Seven 
days later, the levels of murine IgG in the culture supernatant were determined by enzyme-
linked immunosorbent assay (ELISA).  
For B cell proliferation assay, FACS-sorted 1 × 10
5
 naïve B cells labeled with CFSE 
(carboxyfluorescein diacetate succinimidyl ester, Invitrogen) were co-cultured with 5 × 10
4
 
CXCR5
+
 or CCR6
+
 CD4 T cells as described above. The percent of divided cells was 
determined by flow cytometry. 
10. ELISA 
To measure the levels of antibodies to dsDNA and histone in circulation, serum was 
collected from the wild type or BXD2 mice at various time points and was measured by 
ELISA as described previously [118]. Briefly, ELISA plates (Greiner Bio-one or Nunc) were 
coated with 0.01% of poly-L-lysine (Sigma-Aldrich) for 1 hour prior to coating with 5 μg/ml 
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of calf thymus dsDNA (Sigma-Aldrich) and 5 μg/ml histone (from calf thymus, Sigma-
Aldrich) overnight at 37°C.  The plates were blocked for 2 hours with PBS-Tween 20 (PBST) 
plus 3% milk. Sera were diluted in PBS with 1% of FBS, were transferred to the plates and 
were incubated for 2 hours at room temperature. Then the assay was performed with HRP-
conjugated total IgG detection antibody.   
To measure the levels of IgG produced by B cells in vitro, total murine IgG was 
quantified in culture supernatants with a total IgG capture antibody (Donkey anti-mouse IgG 
(H+L), Jackson ImmunoResearch) and HRP-conjugated total IgG detection antibody.  
NP-specific IgM and IgG antibodies in sera obtained from NP-KLH immunized mice 
were measured by ELISA. ELISA plates were coated with 5 μg/ml of NP4-BSA (for high 
affinity) or NP32-BSA (for general affinity, all from Biosearch Technologies). The plates 
were blocked for 2 hours in PBS with 10 % FBS. Serum samples were added in a three-fold 
serial dilution in PBS with 1% FBS, followed by HRP-conjugated IgM or total IgG detection 
antibody (Goat anti-mouse IgM or IgG, SouthernBiotech). 
11. Quantitative real-time RT-PCR 
Total RNA was extracted from splenocytes (1×10
6
 cells) or retrovirus transduced 
cells (3×10
5
 cells) with TRIzol (Invitrogen) and reverse transcribed using amfiRivert reverse 
transcriptase (GenDepot) according to the manufacturer’s protocol. Gene expression was 
measured with iTaq-SYBR Green Supermix (Bio-Rad Laboratories) and the ABI-PRISM 
7900 detection system (Applied Biosystems). Data were normalized to expression of the β-
actin gene. The primer pairs used in quantitative RT-PCR are described in Table 5.  
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12. Statistical analysis 
Data were analyzed with GraphPad Prism 5 (GraphPad). Statistics was calculated 
with the two-tailed Student’s t-test. For correlative analyses among the percent of GL7+Fas+ 
germinal center B cells, the percent of T helper cell subsets, the levels of dsDNA specific 
autoantibodies, linear-regression analysis was performed. p- values below 0.05 were 
considered statistically significant. 
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Table 5. List of real-time PCR primers 
Gene 5’ primer 3’ primer 
Ifng GATGCATTCATGAGTATTGCCAAGT GTGGACCACTCGGATGAGCTC 
Il17 CTCCAGAAGGCCCTCAGACTAC GGGTCTTCATTGCGGTGG 
Il6 TATGAAGTTCCTCTCTGCAAGAGA TAGGGAAGGCCGTGGTT 
Il4 AGATCACGGCATTTTGAACG TTTGGCACATCCATCTCCG 
Il10 ATAACTGCACCCACTTCCCAGTC CCCAAGTAACCCTTAAAGTCCTGC 
Il21 TCATCATTGACCTCGTGGCCC ATCGTACTTCTCCACTTGCAATCCC 
Tbx21 CAACAACCCCTTTGCCAAAG TCCCCCAAGCAGTTGACAGT 
Rorc CCGCTGAGAGGGCTTCAC TGCAGGAGTAGGCCACATTACA 
Bcl6 AGGCCTCCTTCCGCTACAAG CAAATGTTACAGCGATAGGGTTTCT 
Foxp3 GGCCCTTCTCCAGGACAGA GCTGATCATGGCTGGGTTGT 
Icos CGGCAGTCAACACAAACAA TCAGGGGAACTAGTCCATGC 
Pdcd1 CCGCCTTCTGTAATGGTTTGA GGGCAGCTGTATGATCTGGAA 
Ctla4 ACTCATGTACCCACCGCCTA GGGCATGGTTCTGGATCAAT 
Prdm1 ACATAGTGAACGACCACCCCTG CTTACCACGCCAATAACCTCTTTG 
Cxcr5 ACTCCTTACCACAGTGCACCT GGAAACGGGAGGTGAACCA 
Ccr6 CCTCACATTCTTAGGACTGGAGC GGCAATCAGAGCTCTCGGA 
Ascl2 CGCTGCCCAGACTCATGCCC GCTTTACGCGGTTGCGCTCG 
Id3 TGCTACGAGGCGGTGTGCTG AGTGAGCTCAGCTGTCTGGATCGG 
Actb TGGAATCCTGTGGCATCCATGAAAC TAAAACGCAGCTCAGTAACAGTCCG 
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